A lipid binding peptide
Lipebodies address production and delivery challenges of antibody-based therapies by forming a lipid bilayer for stable, scalable, and efficient tumor penetration with high payload capacity and dual antigen-binding capabilities.
Patent Information
- Application Number
- PCT/IB2026/054487
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing antibody-based therapies face challenges such as complex production processes, batch-to-batch variability, high costs, stability issues, limited payload capacity, antigen heterogeneity, immunogenicity, and poor tumor penetration, which hinder their scalability and therapeutic efficacy.
Development of lipid-binding peptides (lipebodies) that form a lipid bilayer conformation, allowing for easy production in E. coli, enhanced stability, high payload capacity, and deep tumor penetration, with dual or multiple antigen-binding capabilities.
Lipebodies offer stable, scalable, and cost-effective therapeutic options with improved tumor penetration and payload delivery, reducing immunogenicity and enhancing therapeutic efficacy across diverse antigen expressions.
Smart Images

Figure IB2026054487_12112026_PF_FP_ABST
Abstract
Description
[0001] Title of the invention
[0002] A lipid binding peptide
[0003] Field of the invention
[0004] The present invention relates to lipid binding peptides. Also disclosed are lipid-peptide conjugates comprising the lipid binding peptides. The lipid binding peptides and lipid-peptide conjugates can comprise at least one active agent, making the lipid binding peptides and lipid-peptide conjugates useful in therapy and for use in a method of preventing or treating a disease or disorder, or in the manufacture of a medicament for preventing or treating a disease or disorder.
[0005] Background to the invention
[0006] Although traditional antigen binding peptides, such as monoclonal antibodies and bispecific antibodies offer targeted therapeutic approaches, their production processes are inherently complex, costly, and challenging to scale consistently. Bispecific antibodies require intricate genetic engineering to combine two distinct antigen-binding specificities within a single molecule. This complexity can result in batch-to-batch variability, impacting the reproducibility, scalability, and overall affordability of antibody-based therapies. Furthermore, antibody products commonly necessitate specific storage conditions to maintain their biological stability, potency, and therapeutic efficacy.
[0007] As alternatives to conventional antibodies and bispecific antibodies, smaller recombinant antibody derivatives, such as single-chain variable fragments (scFv), diabodies, and other antibody fragment-based molecules, have emerged. The scFv construct comprises antibody variable heavy (VH) and variable light (VL) domains joined by a flexible peptide linker (e.g., 15-20 amino acids). Diabodies represent another alternative format comprising non-covalently associated VH-VL dimers derived from scFv fragments containing shortened linkers (e.g., 5 amino acids). scFvand diabodies offer advantages including simplified recombinant production in microbial or yeast expression systems, improved tissue penetration due to reduced molecular size (e.g., 25 kDa and 55KDa respectively), and rapid systemic clearance, which is advantageous for diagnostic imaging applications. Despite these benefits, scFvand diabodies possess notable limitations for therapeutic use. scFv often display reduced stability in physiological environments, resulting in aggregation, rapid systemic clearance, and shorter serum half-lives, thereby requiring repeated dosing or sophisticated stabilization strategies such as PEGylation or fusion with serum-albumin binding domains. Furthermore, scFv molecules can demonstrate reduced binding affinity and avidity due to monovalent antigen recognition, thus potentially limiting their therapeutic efficacy. Diabodies, while addressing some of the stability issues inherent in scFv, still exhibit limitations including potential instability in vivo due to the non-covalent nature of VH-VL interactions. Diabody assembly can be susceptible to mispairing of chains or subunit dissociation, complicating consistent manufacturing and formulation. Moreover, their relatively small size results in rapid renal clearance and short serumhalf-life, necessitating frequent dosing or additional molecular modifications to prolong their therapeutic effectiveness.
[0008] Antibody-drug conjugates (ADCs), typically comprising full-length monoclonal antibodies (e.g., 150 kDa), exhibit a limited payload capacity, a constraint defined by the finite number of conjugation sites available on the antibody structure. Typically, ADC payload capacity is expressed as the drug-to-antibody ratio (DAR), which quantifies the average number of cytotoxic molecules covalently attached to a single antibody molecule. In general, ADCs exhibit DAR values ranging from 2 to 8, with most clinically approved ADCs having a DAR around 3 to 4. Trastuzumab deruxtecan (Enhertu®) exhibits one of the highest DAR of approximately 8. This limitation of payload capacity stems primarily from structural constraints of antibodies and the physicochemical properties of the conjugation sites, typically lysine residues or engineered cysteine residues. Higher DAR values often result in increased hydrophobicity and aggregation tendencies, negatively impacting solubility, pharmacokinetics, and stability of ADCs. Furthermore, low DAR values may lead to suboptimal therapeutic potency, as fewer cytotoxic molecules are delivered per antibody binding event, potentially reducing the capacity of ADCs to effectively eliminate target cancer cells, especially those expressing low or heterogeneous antigen levels. Consequently, balancing DAR is a critical consideration in ADC design, necessitating a compromise between therapeutic potency, pharmacokinetic stability, solubility, aggregation propensity, and systemic toxicity. Manufacturing processes for ADCs involve complex and precise conjugation chemistry, frequently resulting in high manufacturing expenses and increased variability in product quality. Such complexities create challenges in scaling production consistently, affecting broader clinical implementation. ADCs commonly exhibit limited chemical stability due to linker degradation or decomposition of cytotoxic drugs, resulting in reduced shelf-life and complex logistics for storage and distribution. Stability issues adversely affect availability, shelf-life management, and global distribution strategies. ADC efficacy relies significantly upon optimal linker stability. Premature linker cleavage may cause release of cytotoxic payloads into systemic circulation, inducing undesirable systemic toxicities. Conversely, overly stable linkers may prevent effective intracellular release of the payload in target tumor cells, diminishing overall therapeutic efficacy. ADCs exhibit restricted penetration into solid tumors or fibrotic tissues. This limited intratumoral penetration arises predominantly from their substantial molecular dimensions, inherent steric hindrance, which impede diffusion through the dense extracellular matrix (ECM) and interstitial spaces characteristic of solid tumors and fibrotic tissues. Additionally, ADCs often encounter elevated interstitial pressure within tumor microenvironments, further restricting efficient distribution beyond peripheral tumor regions. Consequently, ADCs may accumulate preferentially near tumor vasculature, with limited capacity to reach distal tumor cells located deep within tumor tissues, particularly hypoxic or poorly vascularized regions. This penetration barrier significantly compromises the uniformity and completeness of drug delivery, reducing therapeutic efficacy, facilitating tumor-cell survival and promoting resistance development. Thus, the large molecular size and structural complexity of ADC molecules present inherent challenges for achieving homogeneous and effective treatment of solid malignancies, necessitating advanced strategies such as tumor-penetrating peptides and enzymatic matrix degradation to enhance therapeutic distribution and effectiveness.
[0009] Antigen heterogeneity, characterized by inconsistent or reduced target antigen expression across tumor cell populations, significantly reduces therapeutic efficacy and clinical utility of antibody-based therapies, including antibody-drug conjugates (ADCs). This heterogeneity promotes therapeutic resistance and complicates accurate patient stratification, thereby limiting overall clinical outcomes. Strategies to overcome antigen heterogeneity include developing antibody formats capable of recognizing multiple tumor-associated antigens simultaneously, thereby broadening target specificity and increasing the likelihood of effectively engaging tumor cells with varying antigen expression profiles. In this context, multivalent antibody constructs, such as bispecific, trispecific (e.g., trivalent), and multispecific antibodies, have been explored. However, despite their therapeutic promise, the construction and production of multivalent antibodies is very challenging.
[0010] Alternative strategies, such as mixtures of monoclonal antibodies (antibody cocktails), bispecific antibody formats with simpler architectures, or combination therapies involving ADCs and other modalities (immune checkpoint inhibitors, chemotherapy), may also be pursued to address antigen heterogeneity more practically.
[0011] ADCs are susceptible to eliciting immunogenic responses, including formation of antidrug antibodies (ADAs). Such immunogenicity may reduce therapeutic effectiveness, increase risk of adverse immune-mediated reactions, and impose limitations on repeat dosing regimens. Several factors contribute to ADA formation in ADCs: (1) small-molecule payload exposure and recognition: most of the linker-drug conjugation strategies do not shield the cytotoxic drug, leading to immune recognition of the small-molecule payload or the linker-drug complex; (2) conjugation-induced structural modifications: ADCs are typically conjugated via lysine residues (amine conjugation) or cysteine residues (thiol conjugation, e.g., maleimide chemistry). These modifications may alter the antibody's natural conformation, exposing neoepitopes that are recognized as foreign by the immune system. Additionally, stochastic conjugation methods can lead to heterogeneous ADC populations, where some variants may have altered immunogenic profiles; (3) immune system recognition of linkers: some linkers, especially non-natural synthetic linkers, may not be well tolerated by the immune system, triggering ADA responses; and (4) aggregation and protein instability: high drug-to-antibody ratios (DAR), particularly DAR > 6, often increase hydrophobicity and lead to protein aggregation, which is highly immunogenic. Also, charge alterations from conjugation can contribute to aggregation, enhancing ADA formation.
[0012] A more recent development is scFv-drug conjugates. However, scFv typically have a limited payload capacity, with a drug-to-scFv ratio of approximately 1-2. This limited loading results from their small size (e.g., 25-30 kDa), providing fewer accessible conjugation sites compared to full-sized antibodies. Increasing payload beyond this range can negatively impact solubility, stability, and pharmacokinetics. Strategies to improve payload capacity include multimerization (e.g., diabodies) or polymer conjugation (e.g., PEGylation), but these approaches add complexity. Thus, scFv-drug conjugates represent a feasible therapeutic concept under active development, though not yet clinically approved.
[0013] Coupling antibodies to liposome (e.g., encapsulating small molecule) enhances targeted drug delivery but presents several challenges related to efficiency, stability, tissue penetration, andlarge-scale production. Chemical coupling methods, such as maleimide-thiol orNHS-amine reactions, often result in low conjugation efficiency, potential loss of antibody binding activity, and random orientation issues that may hinder target recognition. Additionally, PEGylated lipids, which enhance liposome circulation time, can reduce antibody accessibility to target cells, limiting therapeutic effectiveness. From a manufacturing perspective, incorporating antibody production into liposome production adds complexity, requiring numerous purification steps, quality control, and regulatory compliance. Ensuring batch-to-batch consistency is also a challenge due to conjugation heterogeneity, necessitating advanced analytical techniques like DLS, size exclusion chromatography, and SPR for quality control. Furthermore, high production costs associated with antibody purification, conjugation optimization, and stability testing make large-scale commercialization very challenging. The bulkiness of antibody-decorated liposomes is a major limitation for deep tumor penetration. Larger nanoparticles, especially those exceeding 100 nm, face difficulty penetrating the tumor interstitium due to high intratumoral pressure and dense extracellular matrix (ECM). Liposomal nanocarriers typically range from 100 to 200 nm in diameter, while the addition of antibodies (e.g., 150 kDa, 10 nm in length) further increases the overall hydrodynamic size of the conjugate.
[0014] Antibody and bispecific antibody production is complex and costly. The production of bispecific antibodies involves the complex engineering to combine two different antigen-binding specificities. This complexity can affect consistency of production. Furthermore, this complexity can impact the scalability and affordability of antibody-based therapies. Antibodies and bispecific antibodies may require specific storage conditions to maintain their stability and activity. Antibodydrug conjugates (ADCs) have a limited payload capacity, limiting the amount of small molecules or cytotoxic drugs that can be conjugated to the antibody. This can impact the potency of the ADC and its ability to effectively modulate / kill target cells.
[0015] Summary of the invention
[0016] According to a first aspect of the present invention there is provided a lipid binding peptide comprising at least one lipid binding domain.
[0017] Optionally, the lipid binding peptide comprises at least one hydrophobic amino acid and at least one hydrophilic amino acid. Further optionally, the lipid binding peptide comprises at least one hydrophobic domain and at least one hydrophilic domain. Optionally, the lipid binding peptide is an amphipathic peptide. Further optionally, the lipid binding peptide is a secondary amphipathic peptide. Preferably, the lipid binding peptide is a secondary amphipathic peptide.
[0018] Optionally, the at least one lipid binding domain comprises at least one hydrophobic amino acid and at least one hydrophilic amino acid. Further optionally, the at least one lipid binding domain comprises at least one hydrophobic domain and at least one hydrophilic domain. Optionally, the at least one lipid binding domain is an amphipathic peptide. Further optionally, the at least one lipid binding domain is a secondary amphipathic peptide. Preferably, the at least one lipid binding domain is a secondary amphipathic peptide.
[0019] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one proline. Further optionally, the lipid binding peptide and / or the at least onelipid binding domain comprises at least two, three, four, or five prolines. Optionally, at least 15% of the amino acids of the amino acid sequence of the lipid binding peptide and / or the at least one lipid binding domain are proline. Optionally, at least 20%, optionally at least 25%, optionally at least 20%, optionally at least 25%, optionally at least 30% of the amino acids of the amino acid sequence of the lipid binding peptide and / or the at least one lipid binding domain are proline.
[0020] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one proline and at least one hydrophilic amino acid. Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two, three, four, or five prolines and at least two, three, four, or five hydrophilic amino acids. Optionally, the at least one proline and the at least one hydrophilic amino acid are tandemly interspersed.
[0021] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one proline and at least one arginine. Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two, three, four, or five prolines and at least two, three, four, or five arginines. Optionally, the at least one proline and the at least one arginine are tandemly interspersed.
[0022] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises the amino acid sequence ZXZPPP (SEQ ID NO: 10) wherein Z is any hydrophobic amino acid and X is any hydrophilic amino acid. Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one domain having the amino acid sequence ZXZPPP (SEQ ID NO: 10). Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one domain having the amino acid sequence ZXZPPP (SEQ ID NO: 10) wherein the at least one domain is tandemly interspersed. Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two domains having the amino acid sequence ZXZPPP (SEQ ID NO: 10) wherein the at least two domains are tandemly interspersed.
[0023] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one lysine and at least one leucine. Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two, three, four, or five lysines and at least two, three, four, or five leucines. Optionally, the at least one lysine and the at least one leucine are tandemly interspersed.
[0024] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises the amino acid sequence LKKLLK (SEQ ID NO: 11). Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one domain having the amino acid sequence LKKLLK (SEQ ID NO: 11). Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one domain having the amino acid sequence LKKLLK (SEQ ID NO: 11) wherein the at least one domain is tandemly interspersed. Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two domains having the amino acid sequence LKKLLK (SEQ ID NO: 11) wherein the at least two domains are tandemly interspersed. Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least 20 to 100 domains having the amino acid sequence LKKLLK (SEQ ID NO: 11).
[0025] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one lysine, at least one glutamic acid, and at least one leucine. Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two, three, four, or five lysines; at least two, three, four, or five glutamic acids; and at least two, three, four, or five leucines. Optionally, the at least one lysine, at least one glutamic acid, and the at least one leucine are tandemly interspersed.
[0026] Optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises the amino acid sequence LEK. Further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one domain having the amino acid sequence LEK. Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least one domain having the amino acid sequence LEK wherein the at least one domain is tandemly interspersed. Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least two domains having the amino acid sequence LEK wherein the at least two domains are tandemly interspersed. Still further optionally, the lipid binding peptide and / or the at least one lipid binding domain comprises at least 20 to 100 domains having the amino acid sequence LEK.
[0027] Optionally, the lipid binding peptide is displaceable between a first confirmation and a second conformation. Further optionally, the lipid binding peptide is displaceable between a first confirmation and a second conformation in the presence of a lipid. Still further optionally, the lipid binding peptide is displaceable from a first confirmation to a second conformation in the presence of a lipid. Still further optionally, the lipid binding peptide is displaceable from a first confirmation to a second conformation in the presence of a lipid to form a lipid-peptide conjugate.
[0028] Optionally, in the first conformation, the respective terminal ends of the lipid binding peptide are spaced apart. Further optionally, in the first conformation, first and second respective terminal ends of the lipid binding peptide are spaced apart.
[0029] Optionally, in the second conformation, the lipid binding peptide at least partially circumscribes at least one lipid. Further optionally, in the second conformation, the lipid binding peptide circumscribes the at least one lipid. Still further optionally, in the second conformation, the lipid binding peptide circumscribes the at least one lipid at least once. Still further optionally, in the second conformation, the lipid binding peptide circumscribes the at least one lipid at least twice. Preferably, in the second conformation, the lipid binding peptide circumscribes the lipid twice.
[0030] Optionally, in the second conformation, the respective terminal ends of the lipid binding peptide are adjacently spaced. Further optionally, in the second conformation, first and second respective terminal ends of the lipid binding peptide are adjacently spaced.
[0031] Optionally, in the second conformation, the lipid binding peptide comprises at least one alpha-helix. Optionally, in the second conformation, the lipid binding peptide comprises at least one beta-sheet. Optionally, in the second conformation, the lipid binding peptide comprises at least one alpha-helix and at least one beta-sheet. Preferably, in the second conformation, the lipid binding peptide comprises at least one alpha-helix.
[0032] Optionally, the at least one lipid binding domain is a polyamino acid. Further optionally, the at least one lipid binding domain is a peptide. Still further optionally, the at least one lipid binding domain is a protein.
[0033] Optionally, the at least one lipid binding domain is an apolipoprotein or a fragment thereof. Further optionally, the at least one lipid binding domain is an apolipoprotein selected from apolipoprotein A, optionally Apo-Al, Apo-A2, Apo-A4, orApo-A5; Apolipoprotein B, optionally Apo-B48 or Apo B-100; Apolipoprotein C, optionally ApoC-l, ApoC-ll, ApoC-lll, orApoC-IV;Apolipoprotein D; Apolipoprotein E; Apolipoprotein F; Apolipoprotein H; Apolipoprotein J;Apolipoprotein L; and Apolipoprotein M. Optionally, the fragment is at least one alpha-helix of the an apolipoprotein.
[0034] Optionally, the at least one lipid binding domain comprises an amino acid sequence selected from SEQ ID NO: 11 to SEQ ID NO: 25.
[0035] Optionally, the at least one lipid binding domain comprises the amino acid sequence LKKLLK (SEQ ID NO: 11) wherein Z is any hydrophobic amino acid and X is any hydrophilic amino acid.
[0036] Optionally, the lipid binding peptide further comprises at least one antigen binding domain. Further optionally, the lipid binding peptide further comprises at least two antigen binding domains. Preferably, the lipid binding peptide further comprises two antigen binding domains.Further preferably, the lipid binding peptide further comprises first and second antigen binding domains.
[0037] Optionally, the lipid binding peptide comprises at least one lipid binding domain and at least one antigen binding domain. Further optionally, the lipid binding peptide comprises at least one lipid binding domain and at least two antigen binding domains. Preferably, the lipid binding peptide comprises one lipid binding domain and two antigen binding domains. Further preferably, the lipid binding peptide comprises one lipid binding domain and first and second antigen binding domains.
[0038] Optionally, the at least one antigen binding domain is located at a terminal end of the lipid binding peptide. Further optionally, the at least one antigen binding domain is located at a first terminal end of the lipid binding peptide. Further optionally, the first antigen binding domain is located at the first terminal end of the lipid binding peptide. Alternatively, the at least one antigen binding domain is located at a second terminal end of the lipid binding peptide. Further alternatively, the second antigen binding domain is located at the second terminal end of the lipid binding peptide. Still further alternatively, the first antigen binding domain is located at the first terminal end of the lipid binding peptide and the second antigen binding domain is located at the second terminal end of the lipid binding peptide.
[0039] Optionally, the at least one lipid binding domain is located between the at least two antigen binding domains. Further optionally, the at least one lipid binding domain is located between the two antigen binding domains. Further optionally, the at least one lipid binding domain is located between the first and second antigen binding domains.
[0040] Optionally, the lipid binding peptide comprises at least one lipid binding domain and at least one antigen binding domain. Further optionally, the lipid binding peptide comprises at least one lipid binding domain and at least two antigen binding domains. Preferably, the lipid binding peptidecomprises one lipid binding domain and two antigen binding domains. Further preferably, the lipid binding peptide comprises one lipid binding domain first and second antigen binding domains.
[0041] Optionally, the at least one antigen binding domain comprises an antibody. Still further optionally, the at least one antigen binding domain comprises a fragment antigen-binding region of an antibody. Still further optionally, the at least one antigen binding domain comprises a variable region of an antibody. Still further optionally, the at least one antigen binding domain comprises a variable region of a heavy chain of an antibody. Still further optionally, the at least one antigen binding domain comprises a variable region of a light chain of an antibody. Still further optionally, the at least one antigen binding domain comprises a variable region of a heavy chain of an antibody and a variable region of a light chain of an antibody.
[0042] Optionally, the first antigen binding domain comprises a variable region of a heavy chain of an antibody. Further optionally, the second antigen binding domain comprises a variable region of a light chain of an antibody. Still further optionally, the first antigen binding domain comprises a variable region of a heavy chain of an antibody and the second antigen binding domain comprises a variable region of a light chain of an antibody. Optionally, the variable region of the heavy chain and the variable region of the light chain together form a fragment antigen-binding region of an antibody.
[0043] Optionally, the first antigen binding domain comprises a variable region of a heavy chain of an antibody and a variable region of a light chain of an antibody. Further optionally, the second antigen binding domain comprises a variable region of a heavy chain of an antibody and a variable region of a light chain of an antibody. Optionally, the variable region of the heavy chain and the variable region of the light chain together form a fragment antigen-binding region of an antibody. Optionally, the first and second antigen binding domains are the same. Alternatively, the first and second antigen binding domains are different.
[0044] Optionally, in the first conformation of the lipid binding peptide, the at least one antigen binding domain does not bind the antigen. Optionally, in the second conformation of the lipid binding peptide, the at least one antigen binding domain binds the antigen. Optionally, in the first conformation of the lipid binding peptide, the at least one antigen binding domain does not bind the antigen and, in the second conformation of the lipid binding peptide, the at least one antigen binding domain binds the antigen.
[0045] Optionally, the at least one antigen binding domain comprises at least one linker. Further optionally, each antigen binding domain comprises at least one linker. Optionally, the at least one linker is located between each antigen binding domain.
[0046] Optionally, the at least one linker is a flexible linker. Further optionally, the at least one linker is a flexible polymer.
[0047] Optionally, the at least one linker is an amino acid linker. Further optionally, the at least one linker is a peptide linker. Optionally, the linker is a glycine linker. Further optionally, the linker comprises at least one glycine. Further optionally, the linker comprises at least two, three, four, or five glycines. Optionally, the linker is a glycine / serine linker. Further optionally, the linker comprises at least one glycine and at least one serine. Further optionally, the linker comprises at least two, three, four, or five glycines and at least two, three, four, or five serines. Optionally, the at least one glycine and the at least one serine are tandemly interspersed. Optionally, the linker is aglycine / alanine linker. Further optionally, the linker comprises at least one glycine and at least one alanine. Further optionally, the linker comprises at least two, three, four, or five glycines and at least two, three, four, or five alanines. Optionally, the at least one glycine and the at least one alanine are tandemly interspersed. Optionally, the linker is an alanine / serine linker. Further optionally, the linker comprises at least one alanine and at least one serine. Further optionally, the linker comprises at least two, three, four, or five alanine s and at least two, three, four, or five serines. Optionally, the at least one alanine and the at least one serine are tandemly interspersed.
[0048] Optionally, the at least one linker has an amino acid sequence selected from SEQ ID NO:1 to SEQ ID NO:9.
[0049] Optionally, the at least one linker is a separable linker. Further optionally, the at least one linker is a cleavable linker. Still further optionally, the at least one linker is a cleavable amino acid linker. Still further optionally, the at least one linker is a protease-cleavable amino acid linker.
[0050] Optionally, the at least one linker has an amino acid sequence selected from SEQ ID NO:26 to SEQ ID NO:29.
[0051] Optionally, the at least one antigen binding domain comprises at least one cap peptide. Further optionally, each antigen binding domain comprises at least one cap peptide. Optionally, the at least one cap peptide is located at a terminal end of the at least one antigen binding domain. Further optionally, the at least one cap peptide is located at a terminal end of each antigen binding domain.
[0052] Optionally, the at least one cap peptide is a separable cap peptide. Further optionally, the at least one cap peptide is a cleavable cap peptide. Still further optionally, the at least one cap peptide is a protease-cleavable cap peptide.
[0053] Optionally, the at least one cap peptide has an amino acid sequence selected from SEQ ID NO: 30 to SEQ ID NO:35.
[0054] Optionally, the at least two antigen binding domains are the same antigen binding domains. Further optionally, the two antigen binding domains are the same antigen binding domains. Still further optionally, the first and second antigen binding domains are the same antigen binding domains. Optionally, the at least two antigen binding domains are different antigen binding domains. Further optionally, the two antigen binding domains are different antigen binding domains. Still further optionally, the first and second antigen binding domains are different antigen binding domains.
[0055] Optionally, the lipid binding peptide further comprises at least one T-cell antigen binding domain. Further optionally, the lipid binding peptide further comprises a T-cell antigen binding domain. Still further optionally, the lipid binding peptide comprises at least one lipid binding domain, at least one antigen binding domain and at least one T-cell antigen binding domain. Still further optionally, the lipid binding peptide comprises at least one lipid binding domain, at least two antigen binding domains and at least one T-cell antigen binding domain. Still further optionally, the lipid binding peptide comprises at least one lipid binding domain, at two antigen binding domains and a T-cell antigen binding domain.
[0056] Optionally, the lipid binding peptide further comprises at least one intermolecular linker. Further optionally, the at least one lipid binding domain further comprises at least one intermolecular linker.
[0057] Optionally, the at least one intermolecular linker is an intrachain intermolecular linker. Alternatively, the at least one intermolecular linker is an interchain intermolecular linker.
[0058] Optionally, the at least one intermolecular linker extends between at least two amino acid residues. Optionally, the at least one intermolecular linker extends between at least two cysteine residues. Further optionally, the at least one intermolecular linker is a covalent linker extending between at least two cysteine residues. Still further optionally, the at least one intermolecular linker is a disulfide bond extending between at least two cysteine residues. Optionally, the at least one intermolecular linker extends between at least two leucine residues. Further optionally, the at least one intermolecular linker is a non-covalent linker extending between at least two leucine residues. Still further optionally, the at least one intermolecular linker is a hydrogen bond linker extending between at least two cysteine residues. Still further optionally, the at least one intermolecular linker is an electrostatic bond linker extending between at least two cysteine residues.
[0059] Optionally, the at least one intermolecular linker comprises an amino acid sequence selected from SEQ ID NO: 56 to SEQ ID NO: 68.
[0060] Optionally, the lipid binding peptide comprises an amino acid sequence selected from SEQ ID NO: 36 to SEQ ID NO: 54 or SEQ ID NO: 80 to SEQ ID NO:85.
[0061] According to a second aspect of the present invention there is provided a lipid-peptide conjugate comprising at least one lipid binding peptide according to the first aspect of the present invention; and at least one lipid.
[0062] Optionally, the at least one lipid comprises at least one hydrophobic domain and at least one hydrophilic domain. Optionally, the at least one lipid is an amphipathic lipid. Further optionally, the at least one lipid is a secondary amphipathic lipid. Preferably, the at least one lipid is a secondary amphipathic lipid. Optionally, the at least one lipid comprises at least two hydrophobic domains and at least one hydrophilic domain. Optionally, the at least one lipid comprises at two hydrophobic domains and one hydrophilic domain.
[0063] Optionally, the at least one lipid is selected from a phospholipid, a sphingolipid, and combinations thereof.
[0064] Optionally, the phospholipid is selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), cardiolipin, and combinations thereof.
[0065] Optionally, the sphingolipid is selected from sphingomyelin, a glycolipid, and combinations thereof.
[0066] Optionally, the lipid-peptide conjugate comprises a lipid layer. Further optionally, the lipid-peptide conjugate comprises a lipid bilayer. Preferably, the lipid-peptide conjugate comprises a lipid bilayer. Optionally, the lipid-peptide conjugate comprises a spherical lipid layer. Further optionally, the lipid-peptide conjugate comprises a spherical lipid bilayer. Optionally, the lipid-peptide conjugate comprises a discoidal lipid layer. Further optionally, the lipid-peptide conjugate comprises a discoidal lipid bilayer. Preferably, the lipid-peptide conjugate comprises a spherical lipid bilayer.
[0067] Optionally, the at least one lipid binding peptide at least partially circumscribes the at least one lipid. Further optionally, the at least one lipid binding peptide circumscribes the at least one lipid. Still further optionally, the at least one lipid binding peptide circumscribes the at least one lipid at least once. Still further optionally, the at least one lipid binding peptide circumscribes the at least one lipid at least twice. Preferably, the at least one lipid binding peptide circumscribes the at least one lipid twice.
[0068] Optionally, the lipid-peptide conjugate has a diameter of at least 5 nm. Further optionally, the lipid-peptide conjugate has a diameter of at least 10, optionally at least 15, optionally at least 20, optionally at least 25, optionally at least 30, optionally at least 35, optionally at least 40, optionally at least 45, optionally at least 50 nm.
[0069] Optionally, the lipid-peptide conjugate has a diameter of less than 50 nm. Further optionally, the lipid-peptide conjugate has a diameter of less than 45, optionally less than 40, optionally less than 35, optionally less than 30, optionally less than 25, optionally less than 20, optionally less than 15, optionally less than 10 nm.
[0070] Optionally, the lipid-peptide conjugate further comprises at least one molecule.
[0071] Optionally, the at least one molecule is a therapeutic molecule. Further optionally, the at least one molecule is an active agent. Still further optionally, the lipid-peptide conjugate further comprises at least one active agent.
[0072] Optionally, the at least one molecule is a nucleic acid. Further optionally, the at least one molecule is a polynucleic acid. Still further optionally, the at least one molecule is an oligonucleotide. Still further optionally, the at least one molecule is a ribonucleic acid. Still further optionally, the at least one molecule is a deoxyribonucleic acid.
[0073] Optionally, the at least one molecule is an amino acid. Further optionally, the at least one molecule is a polyamino acid. Still further optionally, the at least one molecule is a peptide. Still further optionally, the at least one molecule is a protein.
[0074] According to a third aspect of the present invention, there is provided a lipid binding peptide according to the first aspect of the present invention or a lipid-peptide conjugate according to the second aspect of the present invention for use in therapy.
[0075] According to a fourth aspect of the present invention, there is provided a method of preventing or treating a disease or disorder in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically-effective amount of a lipid binding peptide according to the first aspect of the present invention or a lipid-peptide conjugate according to the second aspect of the present invention.
[0076] According to a fifth aspect of the present invention, there is provided use of a lipid binding peptide according to the first aspect of the present invention or a lipid-peptide conjugate according to the second aspect of the present invention in the manufacture of a medicament for preventing or treating a disease or disorder.
[0077] Optionally, the disease or disorder is selected from an autoimmune disease, a cancer, and an inflammatory disorder.
[0078] According to a sixth aspect of the present invention, there is provided a nucleic acid encoding an amino acid sequence of the lipid binding peptide according to the first aspect of the present invention.
[0079] Optionally, the nucleic acid encoding an amino acid sequence of the lipid binding peptide is a vector.
[0080] According to a seventh aspect of the present invention, there is provided a host cell comprising the nucleic acid according to a sixth aspect of the present invention.
[0081] Optionally, the host cell is a bacterial cell. Further optionally, the host cell is an Escherichia bacterial cell. Still further optionally, the host cell is an Escherichia coli bacterial cell.
[0082] Unlike monoclonal antibodies and bispecific antibodies, lipid-peptide conjugates (lipebodies) can be produced in Escherichia coli or other hosts, allowing for quick and cost-effective production in large quantities. The prolonged circulation half-life of a lipebody helps with tumor accumulation more than antibodies or other lipid-based nanoparticles. A lipebody is more stable compared to conventional antibodies and bispecific antibodies. A lipebody enables the incorporation of multiple ScFv or nanobodies against different tumor associated antigens. A lipebody, with its unique structure of phospholipid bilayer, offers high loading capacity and easy loading of different small molecules drugs. The compact size of a lipebody is expected to lead to higher tumor accumulation and deep tissue penetration especially in desmoplastic tumors.
[0083] The present invention relates to a new class (platform technology) of antibody-like lipidpeptide conjugate molecules, termed lipebodies, which are made from a lipid binding peptide, which can be a single polypeptide, termed loopable proteins (LPs) having a central lipid binding domain (LBD) and variable antigen-binding domains at the N- and / or C- termini (see Figure 1). The LBD sequence has secondary amphipathic character. In a presence of lipids that can form a bilayer, the hydrophobic face of the lipid binding domain interacts with the acyl chains of the lipid molecules forming a discoidal or spherical shaped bilayer. As a result of the lipid association, the LBD changes its conformation and wraps around the lipid bilayer, optionally at least twice. As a result, the N- and C- termini of the loopable protein move closer to each other, bringing the antigen-binding domains in proximity (see Figure 3).
[0084] Similar to monoclonal antibodies, a lipebody can be used in treatment of many diseases. A lipebody can be designed to act as monospecific, bispecific or multispecific therapeutic molecule. Some key aspects of how a lipebody can be used therapeutically include:
[0085] Monoclonal (or monospecific) lipebody therapy, which involves the use of lipebodies that are designed to target specific antigens on cells. These monospecific lipebodies can be used to treat various conditions, including autoimmune diseases, cancer, and inflammatory disorders.
[0086] Bispecific lipebody therapy, which can target two different antigens or receptors, opening up new possibilities for therapeutic interventions. This dual targeting can be used to redirect immune cells to specific targets, block two different signaling pathways simultaneously, or deliver therapeutic payloads to specific cells. The arms of a bispecific lipebody can be designed in various formats, such as Fab, nanobody or single-chain variable fragments (scFv). These formats can influence the pharmacokinetics and tissue penetration. A bispecific lipebody can be designed to recruit immune cells to attack cancer cells or to block multiple signalling pathways involved in disease progression.Lipebodies can be used in organ transplantation to reduce the risk of rejection by targeting specific immune cells involved in the rejection process. Bispecific lipebodies can be engineered to redirect T-cells to specifically target cancer cells, a strategy known as chimeric antigen receptor (CAR) T-cell therapy. This CAR approach has shown significant success in treating certain types of blood cancers. Bispecific lipebodies can also be used to simultaneously block two different immune checkpoint molecules, enhancing the immune response against cancer or other diseases.
[0087] A bispecific (or monospecific) lipebody can be utilized to deliver therapeutic payloads, such as small molecules, toxins, radioactive isotopes, ASO and siRNA directly to target cells. This targeted delivery minimizes damage to healthy tissues.
[0088] Additionally, a lipebody can be used in various diagnostic tests to detect the presence of specific antigens or pathogens.
[0089] The lipebody molecule is formed a from lipid-binding domain (LBD) having secondary amphipathic character so that, in the presence of at least one lipid capable of forming a lipid bilayer, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of a lipid bilayer from the at least one lipid. In an antibody-like protein, the C-terminus of either or both of a conventional antibody heavy chain (HC) or a conventional antibody light chain (LC) is fused with the LBD. In an antibody-like protein fragment, an antigen binding domain is fused to the C-terminus of the LBD; and wherein the antigen binding domain is selected from an ScFv, a nanobody, a peptide, ora minibinder protein. The lipebody contains at least an N-terminal antigen binding domain; at least one lipid-binding domain (LBD); and a C-terminal antigen binding protein. The at least two variable domains that can be engineered to recognize a specific protein(s).
[0090] An additional T cell inactivating domain can be added to the T cell-engaging bispecific versions of the lipebody to regulate and control the activity of T cells in the context of targeted therapy. For example, a bispecific T cell-engager lipebody can be engineered to contain 4 domains: two antigen-binding domains with one that binds to a tumor-specific antigen and the other that binds to a T cell surface marker, such as CD3, a T cell inactivating / regulating domain that serve as a mechanism to prevent excessive T cell activation and associated toxicities while still allowing for T cell engagement and tumor cell killing and a fourth lipid binding domain that can be loaded with small molecules. The T-cell inactivating / regulating domain can take various forms, such as a peptide or engineered inhibitory domain that dampen T cell signaling. The T-cell inactivating / regulating domain can be cleaved only at the tumor microenvironment (TME) with the help of TME specific enzyme or low pH, exposing CD3 binding domains. Thus, T cells can be activated specifically within the tumor microenvironment enhancing therapeutic efficacy while minimizing off-target effects.
[0091] Small molecules can be easily loaded into the lipebody to produce therapeutic molecules similar to antibody-drug conjugate (ADC), but with higher loading capacity.
[0092] Unlike traditional antibodies, the lipebody molecules are essentially one single chain or polypeptide, making them very easy to produce and scale up as it can be expressed in E. coli (or other host organisms). A cleavable affinity tag can be appended to the molecules to facilitate its purification.
[0093] The lipebody constructs can be designed to include intramolecular disulfide bond(s) near the N and C termini of lipid binding domain bringing the variable domains into close proximity. Also, additional disulfide bonds can be appended within the lipid binding domain to further stabilize the lipebody structure.
[0094] Accordingly, the present invention provides a lipid-binding domain (LBD); wherein the lipid binding domain (LBD) sequence has secondary amphipathic character so that, in the presence of at least one lipid capable of forming a lipid bilayer, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of a lipid bilayer from the at least one lipid.
[0095] The invention also provides an antibody-like protein, wherein the C-terminus of either or both of a conventional antibody heavy chain (HC) ora conventional antibody light chain (LC) is fused with the LBD.
[0096] The invention also provides an antibody-like protein fragment, wherein an antigen binding domain is fused to the C-terminus of the LBD of the first aspect of the invention; and wherein the antigen binding domain is selected from an ScFv, a nanobody, a peptide, ora minibinder protein.
[0097] The invention also provides a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antigen binding domain; at least one lipid-binding domain (LBD) of the first aspect of the invention; and a C-terminal antigen binding protein. This corresponds with the embodiment illustrated in Figure 1.
[0098] In the presence of at least one lipid capable of forming a lipid bilayer, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of a lipid bilayer from the at least one lipid. In the presence of at least one lipid capable of forming a lipid bilayer, the LBD changes its conformation to loop around the at least one lipid, at least twice, thereby supporting the formation of a lipid bilayer from the at least one lipid.
[0099] A sequence may have primary or secondary amphipathic character. Primary amphipathic sequences typically have sequentially hydrophilic and hydrophobic amino acids in their primary structure. Secondary amphipathic sequences can adopt an alpha-helix or beta-sheet secondary structure, typically being highly hydrophobic on one face, and hydrophilic (cationic, anionic or polar) on the other face. The lipid binding domain (LBD) sequence has secondary amphipathic character.
[0100] Optionally, the loopable protein comprises, from N-terminus to C-terminus: an antibody domain is one of a heavy chain (HC) domain or a light chain (LC) domain; a linker; at least one lipid-binding domain (LBD) that is, optionally, an amphipathic alpha helix domain; and a complementary antibody domain selected from the other of a heavy chain (HC) domain or the light chain (PC) domain, wherein the HC domain and the LC domain form at least one disulfide bond between the loopable protein and the complementary antibody domain. In the Figure 21 embodiment, LC or HC must be at the N-terminus.
[0101] Optionally, in the loopable protein, the N-terminal antigen binding domain comprises at least first and second binding motifs, wherein the first binding motif is one of VH or VL and the second binding motif is the other of VL or VH, and the two binding motifs are separated by a flexible linker; and / or wherein the C-terminal antigen binding domain comprises at least first and secondbinding motifs, wherein the first binding motif is one of VH or VL and the second binding motif is the other of VL or VH, and the two motifs are separated by a flexible linker. Further optionally, in the loopable protein, the N-terminal first and second binding motifs VL and VH interact with each other or cross interact with the C-terminal first and second binding motifs; and / or wherein the C-terminal first and second binding motifs VL and VH interact with each other or cross interact with the N-terminal first and second binding motifs.
[0102] The linker of the loopable protein may be selected from glycine polymers (G)n; glycineserine polymers (Gi-sSi-5)n, where n is an integer of at least one, two, three, four, or five; glycinealanine polymers; alanine-serine polymers; and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured, and therefore may be able to serve as a neutral tether between domains of the proteins described herein. Glycine accesses significantly more phi-psi space than alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). The ordinarily skilled artisan will recognize that design of a protein in particular embodiments can include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure to provide for a desired lipebody structure. Other exemplary linkers include, but are not limited to the following amino acid sequences: GGG; DGGGS (SEQ ID NO: 1); TGEKP (SEQ ID NO: 2) (see, Liu et al., PNAS 5525-5530 (1997)); GGRR; (GGGGS)nwherein n = 1, 2, 3, 4 or 5 (SEQ ID NO: 3) (see Kim et al., PNAS 93, 1156-1160 (1996.); EGKSSGSGSESKVD (SEQ ID NO: 4) (see Chaudhary et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070); KESGSVSSEQLAQFRSLD (SEQ ID NO: 5) (see Bird et al., 1988, Science 242:423-426), GGRRGGGS (SEQ ID NO: 6);LRQRDGERP (SEQ ID NO: 7); LRQKDGGGSERP (SEQ ID NO: 8); LRQKD(GGGS)2ERP (SEQ ID NO: 9). Alternatively, flexible linkers can be rationally designed using a computer program capable of modeling both lipid-binding sites and the peptides themselves.
[0103] Optionally, in this loopable protein, upon lipid association, the N-terminal antigen binding domain and the C-terminal antigen binding domain move closer to each other, enhancing the avidity of the loopable protein to its target antigen(s).
[0104] Optionally, in the loopable protein, the N-terminal antigen binding domain has the same amino acid sequence as the C-terminal antigen binding domain. Alternatively, in the loopable protein, the N-terminal antigen binding domain and C-terminal antigen binding domain have different amino acid sequences.
[0105] Optionally, in the loopable protein, the N-terminal antigen binding domain and the C-terminal antigen binding domain are covalently linked to each other via the at least one lipid-binding domain (LBD). Optionally or additionally, in the loopable protein, the N-terminal antigen binding domain and the C-terminal antigen binding domain directly interact with each other, non-covalently or covalently, as a result of the lipid association with the connecting lipid binding domain (LBD).
[0106] Optionally, in the loopable protein, the N-terminal antigen binding domain and C-terminal antigen binding domain bind to the same antigen or a different antigen. Alternatively, in the loopable protein, the N-terminal antigen binding domain and C-terminal antigen binding domain devoid of their binding activity while in lipid-free conformation, and only regain their binding activity when brought in proximity (less than 2 nm) to each other after adding lipids.
[0107] Optionally, in the loopable protein, the N-terminal antigen binding domain comprises at least first and second binding motifs, wherein the first binding motif is one of VH or VL and the second binding motif is the other of VL or VH, and the two binding motifs are separated by a flexible linker; and / or wherein the C-terminal antigen binding domain comprises at least first and second binding motifs, wherein the first binding motif is one of VH or VL and the second binding motif is the other of VL or VH, and the two motifs are separated by a flexible linker. The respective binding motifs could be VL-VH-LBD-VL-VH, or VH-VL-LBD-VH-VL; and they could form different embodiments, depending on the linker length between the VH-VL / VL-VH. This flexible linker may be selected from glycine polymers (G)n; glycine-serine polymers (Gi-sSi-5)n, where n is an integer of at least one, two, three, four, or five; glycine-alanine polymers; alanine-serine polymers; and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured, and therefore may be able to serve as a neutral tether between domains of the proteins described herein. Glycine accesses significantly more phi-psi space than alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). The ordinarily skilled artisan will recognize that design of a protein in particular embodiments can include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure to provide for a desired lipebody structure. Other exemplary linkers include, but are not limited to the following amino acid sequences: GGG; DGGGS (SEQ ID NO: 1); TGEKP (SEQ ID NO: 2) (see Liu et al., PNAS 5525-5530 (1997)); GGRR;(GGGGS)n wherein n = 1, 2, 3, 4 or 5 (SEQ ID NO: 3) (see Kim et al., PNAS 93, 1156-1160 (1996.); EGKSSGSGSESKVD (SEQ ID NO: 4) (see Chaudhary et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070); KESGSVSSEQLAQFRSLD (SEQ ID NO: 5) (see Bird et al., 1988, Science 242:423-426), GGRRGGGS (SEQ ID NO: 6); LRQRDGERP (SEQ ID NO: 7); LRQKDGGGSERP (SEQ ID NO: 8); and LRQKD(GGGS)2 ERP (SEQ ID NO: 9). Alternatively, flexible linkers can be rationally designed using a computer program capable of modeling both lipid-binding sites and the peptides themselves. In this embodiment, wherein the N-terminal antigen binding domain comprises at least first and second binding motifs and / or wherein the C-terminal antigen binding domain comprises at least first and second binding motifs, the arrangement could be VL-VH-LBD-VL-VH, or VH-VL-LBD-VH-VL. They could form different embodiments, depending on the linker length between the VH-VL / VL-VH. In the Figure 4 embodiment, a long linker between VH and VL will result in an sLDC embodiment (bottom, middle), and a short linker between VH and VL will result in a dL embodiment (top, right). In this embodiment, the N-terminal first and second binding motifs VL and VH may interact with each other or cross interact with the C-terminal first and second binding motifs; and / or wherein the C-terminal first and second binding motifs VL and VH interact with each other or cross interact with the N-terminal first and second binding motifs.
[0108] The loopable protein may further comprise at least one Cys between the N-terminal binding domain and the LBD; and further comprising at least one Cys between the C-terminal antigen binding domain and the LBD domain, wherein the at least one Cys between the N-terminal binding domain and the LBD domain forms a disulfide bond with the at least one Cys between the LBD and the C-terminal antigen binding domain, after the LBD contacts the at least one lipid.Alternatively or additionally, the N-terminal binding domain may be separated from the LBD by a firstLeucine zipper peptide; and the C-terminal antigen binding domain may be separated from the LBD by a second Leucine zipper peptide, wherein the leucine zipper forms after the LBD contacts the at least one lipid.
[0109] In the loopable protein, the LBD with secondary amphipathicity may be selected from the group comprising: an ApoJ polypeptide; or an ApoA-l polypeptide; or an ApoE polypeptide; or at least one alpha helical polypeptide or a repeat thereof; or at least one amphipathic proline-rich polypeptide or a repeat thereof; or at least one repeat of the sequence ZXZPPP (SEQ ID NO: 10); wherein Z is any hydrophobic residue and X is any hydrophilic residue; and wherein, when the LBD is an at least one alpha helical polypeptide, the alpha helical polypeptide optionally has a sequence selected from the group comprising: (LKKLLK)n repeat (SEQ ID NO: 11); (LEK)n repeat;DFLKAFYDKVAEKFKEAAPDWFKAFYDKVAEKFKEAF (SEQ ID NO: 12):LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 13); KLALRLALKAFKAALKLA (SEQ ID NO: 14); RLALDLALRAFKAAWKLA (SEQ ID NO: 15); ELAWDLAFEALDAELKLD (SEQ ID NO: 16); FLKLLKKFLKLFKKLLKLF (SEQ ID NO: 17); WLKLLKKWLKLWKKLLKL (SEQ ID NO: 18); LLKFLKRLLKLLKDLWKLL (SEQ ID NO: 19); WEAAFAEALAEAWAEHLAEALAEAVEALAA (SEQ ID NO: 20); WEAKLAKALAKALAKHLAKALAKALKACEA (EQ ID NO: 21);RAFARALARALKALARALKALAR (SEQ ID NO: 55); GLFEALLELLESLWELLLEA (SEQ ID NO: 22); KLLKLLLKLWKKLLKLLK (SEQ ID NO: 23); DWLKAFYDKVAEKLKEAF (SEQ ID NO: 24);DWFKAFYDKLAEKFKEAF (SEQ ID NO: 78); and DWFKAFYDKVAEKFKEAF (SEQ ID NO: 25), wherein n is an integer from 20 to 100.
[0110] The loopable protein may further comprise a cap peptide N-terminal of the N terminalantigen binding domain and / or C terminal of the C-terminal antigen binding protein; wherein the cap peptide is cleavable to expose the antigen-binding domain(s) at the intended action site. Optionally, the N terminal-antigen binding domains may comprise the heavy chain or light chain; and further comprising a cap peptide N-terminal of the heavy chain or the light chain, and / or C terminal of the C-terminal antigen binding protein or C-terminal of the lipid binding domain; wherein the cap peptide is cleavable to expose the antigen-binding domains at the intended action site.
[0111] The cleavable linker of the loopable protein may be between the cap peptide and the antigen-binding domain and is cleavable by factors enriched at the intended action site in the TME, such proteases (e.g., matrix metalloproteinases [MMPs], cathepsins), low pH conditions (acidic microenvironment), reductive conditions (elevated glutathione [GSH] concentrations), hypoxia-induced enzymes. The cleavable linker of the loopable protein of the fourth aspect of the invention may have a sequence selected from the group consisting of: Protease-sensitive (MMP): GPLGVRG (SEQ ID NO: 26) or PLGLAG (SEQ ID NO: 27); Cathepsin-sensitive: Val-Cit or FRRG (SEQ ID NO: 28); or Redox-sensitive: Disulfide-containing peptide (Cys-XXXX-Cys) where X is any amino acid (SEQ ID NO: 29).
[0112] The cap peptide of the loopable protein may be designed to interact electrostatically or hydrophobically with amino acid residues within the antigen-binding site (paratope), quenching its binding activity until cleavage occurs at the intended action site. The cap peptide of the loopable protein of the fourth aspect of the invention may have a sequence selected from the group consistingof: EKEEVKDL (SEQ ID NO: 30); EDEDEDED (SEQ ID NO: 31); EKDKDEEK (SEQ ID NO: 32); EKLLDLLE (SEQ ID NO: 33); FFWGGFF (SEQ ID NO: 34); or WELLEQKW (SEQ ID NO: 35).
[0113] The loopable protein may further comprise an affinity purification tag at either or both the N and C termini.
[0114] The loopable protein may comprise the sequence of any one of SEQ ID NOs: 36-54.
[0115] The present invention also provides a lipebody comprising: at least one lipid-bilayer forming lipid that can form a lipid bilayer from the at least one lipid; and b) a looped protein comprising the LBD formed, in the presence of at least one lipid, from the loopable protein so that, in the presence of the at least one lipid, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of the lipid bilayer from the at least one lipid. Optionally, the LBD changes its conformation to loop around the at least one lipid at least twice, thereby supporting the formation of the lipid bilayer from the at least one lipid.
[0116] Optionally, in the lipebody, the diameter of the bilayer is greater than about 5 nm; optionally greater than about 10 nm; further optionally greater than about 15 nm; still further optionally greater than about 30 nm; still further optionally about 50 nm.
[0117] The present invention also provides a method of making a lipebody, the method comprising: contacting the loopable protein of the fourth aspect of the invention with a lipid; and performing freeze / thaw cycles, dialysis or removing detergent by hydrophobic beads. Optionally, in the method, the lipid may be solubilized in detergent; or the loopable protein is in solution at a concentration of 1 uM to about 1 mM prior to contacting step. Alternatively or additionally, in the method, the performing step may occur at a temperature of from about 0 °C to about 37 °C; or the performing step may occur at a temperature of from about 0 °C to about 42 °C. Alternatively or additionally, in the method, the ratio of loopable protein to lipids, optionally phospholipids, may be in a molar ratio from about 1 :20 to about 1 :4500; and lipebodies are formed.
[0118] The present invention also provides a lipebody-cargo conjugate (LDC) comprising: at least one lipid that can form a lipid bilayer from the at least one lipid; a cargo; and a looped protein formed, in the presence of at least one lipid, from the loopable protein, so that, in the presence of at least one lipid, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of the lipid bilayer from the at least one lipid.
[0119] Optionally, the cargo is covalently or non-covalently associated with the lipebody, wherein said cargo is optionally selected from the group consisting of: small molecule drugs, peptides, oligonucleotides, siRNA, or protein toxins (see https: / / www.nature.com / articles / s41392-022-00904-4, https: / / www.nature.com / articles / s41573-020-0075- 7, https: / / link.springer.eom / article / 10.1007 / s13273-019-0040-x). Optionally, the cargo is a small molecule drug and the small molecule drug may hydrophobic and is embedded within the lipid bilayer. The hydrophobic small molecule may be incorporated into the lipebody lipid bilayer through passive diffusion or solvent-assisted loading, as is exemplified in Example 6 herein. Alternatively, the small molecule may be amphiphilic and is incorporated via detergent-mediated exchange during lipebody reconstitution, as is exemplified in Example 7 herein. Further alternatively, the small molecule may be hydrophilic and may be encapsulated, if the lipebody forms a discoidal bilayershape or a spherical liposome-like shape with an aqueous core, within the aqueous core using a pH gradient or ion gradient-based active loading method - this is exemplified in Example 8 herein.
[0120] Optionally, the antigen binding domain may be an antibody (such as anti-PD-1 mAb selected from nivolumab or pembrolizumab for the treatment of HER2-expressing cancer), a peptide, or an antibody fragment (optionally selected from Fab (Fragment antigen-binding), scFv, diabodies, or a nanobody). Both pembrolizumab and nivolumab are PD-1 inhibitors used in cancer treatment, but their specific applications and effectiveness can vary depending on the cancer type and HER2 status. Pembrolizumab has shown effectiveness in HER2-positive gastric / esophageal cancer and HER2-negative breast cancer, while nivolumab is approved for HER2-negative gastric adenocarcinoma and esophageal / GEJ adenocarcinoma. Fab is a fragment retaining the antigenbinding site and part of the constant region, while scFv is a smaller fragment containing only the variable regions of heavy and light chains, linked by a peptide linker. Diabodies are dimers of scFv, forming a bivalent, bispecific antibody fragment. A single-domain antibody (sdAb), also known as a nanobody, is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen. With a molecular weight of only 12-15 kDa, single-domain antibodies (sdAbs) are much smaller than common antibodies (150-160 kDa) which are composed of two heavy protein chains and two light chains, and even smaller than Fab fragments (~50 kDa, one light chain and half a heavy chain) and single-chain variable fragments (~25 kDa, two variable domains, one from a light and one from a heavy chain).
[0121] Optionally, the lipid binding domain (LBD) sequence has secondary amphipathic character so that, in the presence of at least one lipid, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of a lipid bilayer from the at least one lipid; and wherein, optionally, the at least one lipid is selected from the group consisting of palmitic acid, myristic acid, stearic acid, oleic acid, cholesterol, DSPE and DOPE, sphingolipids, lipid-anchored cell-penetrating peptides, cationic lipids such as positively charged lipids, lipids having a positive charge, and lipids comprising a head group having a positive charge, for example 1,2-di-0-octadecenyl-3-trimethylammonium-propane (DOTMA), 1 ,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE) and / or 1 ,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and ionizable lipids such as lipids comprising a tertiary amine, for example 4 Hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate (ALC-0315), 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester (SM-102), O-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino) (DLin-MC3-DMA (MC3)), and / or 1,2-dioleoyl-3-dimethylammonium propane (DODAP).
[0122] Alternatively or additionally, the at least one antigen binding domain of the loopable protein may bind to a cancer-specific receptor selected from the group consisting of: HER2 (Human Epidermal Growth Factor Receptor 2), EGFR (Epidermal Growth Factor Receptor), PSMA (Prostate-Specific Membrane Antigen), CD44 (Hyaluronic Acid Receptor), folate receptor a, transferrin receptor (TfR), B7-H3 (CD276), mesothelin (MSLN), MUC1 (Mucin-1), CD133 (Prominin-1), IL13Ra2 (Interleukin-13 Receptor Alpha 2), Claudin 18.2, glypican-3 (GPC3), ROR1 (Receptor Tyrosine Kinase-like Orphan Receptor 1), PD-L1 (Programmed Death-Ligand 1), CEA (Carcinoembryonic Antigen), VEGFR (Vascular Endothelial Growth Factor Receptor), c-Met (Hepatocyte Growth FactorReceptor), AXL (TAM family receptor tyrosine kinase), folate receptor p (FRp), TEM8 (Tumor Endothelial Markers), CD70, Nectin-4, L1CAM (L1 Cell Adhesion Molecule), and DLL3 (Delta-like Protein 3). These cell surface receptors are selectively overexpressed ordysregulated in various cancer types, providing specific binding sites for targeted drug delivery using lipibody-drug conjugate. Alternatively, the at least one antigen binding domain of the loopable protein may bind to an intracellular antigen selected from the group consisting of: mutant p53, KRAS, Bcl-2, survivin, p-catenin, STAT3, and cytoplasmic or nuclear phosphoproteins. Alternatively, at least one antigen binding domain of the loopable protein binds to a fibrosis-associated receptor selected from the group consisting of: PDGFR-p, TGF-p receptor, VEGFR2, integrin avp6, integrin avp3, CXCR4, CCR2, EGFR, CD248, lysyl oxidase (LOX), AXL, DDR1, DDR2, folate receptor p (FRp), TEM8, podoplanin (PDPN), CD36, FGFR1, FGFR2, CD90, CD44, VCAM-1, ICAM-1 , TSPAN8, LPA1, MARCO, CLEC2D, and CD206, wherein said receptor is selectively expressed or upregulated in fibrotic tissues and provides a target for delivery of therapeutic or diagnostic agents embedded in antibody-drug conjugate.
[0123] Optionally, the lipid binding domain (LBD) sequence has secondary amphipathic character so that, in the presence of at least one lipid, the LBD changes its conformation to loop around the at least one lipid, optionally at least twice, thereby supporting the formation of a lipid bilayer from the at least one lipid. Optionally, the at least one lipid is selected from the group consisting of palmitic acid, myristic acid, stearic acid, oleic acid, cholesterol, DSPE and DOPE, sphingolipids, lipid-anchored cell-penetrating peptides, PEGylated lipids, and cationic lipids such as positively charged lipids, lipids having a positive charge, and lipids comprising a head group having a positive charge, for example 1 ,2-di-0-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE) and / or 1 ,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and ionizable lipids such as lipids comprising a tertiary amine, for example 4 Hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate (ALC-0315), 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester (SM-102), O-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino) (DLin-MC3-DMA (MC3)), and / or 1,2-dioleoyl-3-dimethylammonium propane (DODAP), and wherein said lipid moiety enables intracellular delivery of the lipebody by enhancing membrane permeability, promoting cellular uptake, facilitating membrane insertion, endosomal escape, or receptor-independent endocytosis, thereby allowing the antibody to access intracellular antigens or deliver therapeutic payloads for the treatment of diseases comprising cancer, viral infection, and autoimmune disorders.
[0124] The present invention also provides a method of preparing a lipebody-cargo conjugate, the method comprising: dispersing the at least one lipid and the cargo in a solution that optionally comprises a detergent; mixing the dispersed components and a detergent with the loopable protein; removing the detergent to allow self-assembly of the lipebody-drug conjugate; and optionally isolating the lipebody-drug conjugate comprising the therapeutic payload. Optionally, in this method of the invention, the lipebody-drug conjugate may comprise the lipid bilayer stabilized by the lipid binding domain, and wherein the therapeutic payload is incorporated into the lipid bilayer via passive loading, detergent exchange, or active gradient loading. Optionally, in this method of the invention, the detergent is selected from the group consisting of: CHAPS, DDM, DM, Triton X-100, and octylglucoside; and / or the detergent removal may be performed by dialysis, dilution, or absorption using hydrophobic beads.
[0125] The present invention also provides a method of delivering a therapeutic payload to a target tissue in a subject, the method comprising administering to the subject a therapeutically effective amount of the lipebody-cargo conjugate, wherein the cargo is a drug. Optionally, the method further comprises administering to the subject at least one immune checkpoint inhibitor (e.g. an anti-PD-1 antibody). Optionally, or additionally, the lipebody-drug conjugate is administered intravenously, intratumorally, or subcutaneously or intramuscularly. Optionally, the disease is selected from the group consisting of: cancer, fibrosis, autoimmune disease, infectious disease, and neurodegenerative disorders.
[0126] Suitable lipids are amphipathic (or amphiphilic) — that is, they have a hydrophilic (“waterloving”) or polar end and a hydrophobic (“water-fearing”) or nonpolar end. Optionally, the lipids are phospholipids having a polar head group and two hydrophobic hydrocarbon tails. The tails are usually fatty acids, and they can differ in length (they normally contain between 14 and 24 carbon atoms) and can have one or more cis-double bonds (i.e., it is unsaturated), or does not (i.e., it is saturated). Phospholipids usually comprise either a diacylglyceride structures, such as phosphatidic acid (phosphatidate) (PA), phosphatidylethanolamine (cephalin) (PE), phosphatidylcholine (lecithin) (PC), phosphatidylserine (PS), phosphoinositides such as phosphatidylinositol (PI), phosphatidylinositol 3-phosphate (PI3P), phosphatidylinositol 4-phosphate (PI4P), phosphatidylinositol 5-phosphate (PI5P), phosphatidylinositol 4,5-bisphosphate (PIP2) or phosphatidylinositol (3,4,5)-trisphosphate (PIP3); ora phosphosphingolipid structure such as ceramide phosphorylcholine (sphingomyelin) (SPH), ceramide phosphorylethanolamine (sphingomyelin) (Cer-PE) or ceramide phosphoryllipid.
[0127] Phospholipids also comprise glycerophospholipids or phosphoglycerides that are glycerol-based phospholipids. In general, glycerophospholipids use an "sn" notation, which stands for stereospecific numbering. When the letters "sn" appear in the nomenclature, by convention the hydroxyl group of the second carbon of glycerol (2-sn) is on the left on a Fischer projection. The numbering follows the one of Fischer's projections, being 1-sn the carbon at the top and 3-sn the one at the bottom. The advantage of this particular notation is that the spatial configuration (D or L) of the glycero-molecule is determined intuitively by the residues on the positions sn-1 and sn-3. The term glycerophospholipid includes any derivative of glycerophosphoric acid that contains at least one O-acyl, or O-alkyl, or O-alk-1'-enyl residue attached to the glycerol moiety. The phosphate group forms an ester linkage to the glycerol. The two hydrocarbon chains attached to the glycerol are hydrophobic while the polar head, which mainly consists of the phosphate group attached to the third carbon of the glycerol backbone, is hydrophilic.
[0128] Suitable lipids include, but are not limited to phospholipids, such as phosphatidylcholines (lecithin), glycerophospholipids, and mixtures thereof. Phospholipids conjugated with MMP- or cathepsin-sensitive linkers may also be employed. Suitable mixtures include a mixture of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and POPG (1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1 -glycerol))) in a molar 3:2 ratio; DMPC (Dimyristoylphosphatidylcholine): DMPG (1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol ) in a molar 3:1 ratio. Suitable lipids also include POPCand either DSPC or PEGylated DSPC. Suitable lipids also include POPC and 2-Dioleoyl-3-trimethylammonium propane (DOTAP). Suitable lipids also include PEGylated lipids including, but not limited to, DSPE-PEG2000 (DSPE is 1 ,2-Distearoyl-sn-glycero-3-phosphoethanolamine).Suitable lipids also include POPC and cholesterol in a 3:1 molar ratio.
[0129] Small molecules can be easily loaded into the lipebody to produce therapeutic molecules similar to antibody-drug conjugate (ADC), but with higher loading capacity (see Figure 2). The antigen-binding domains at the N- and C- termini can be scFv, nanobody, or antibody fragments of either the same amino acid sequence (monoclonal antibody like) or different sequence (bispecific antibody like) (see Figure 3). Unlike traditional antibodies, the lipebody molecules are usually one single chain or polypeptide, making it very easy to produce and scale up as it can be expressed in microbial or yeast expression systems. Figure 21 depicts potential configurations of a lipebody, wherein the LBD is covalently fused to the C terminus of either the antibody variable heavy (VH) or antibody variable light (VL). In these embodiments, the lipobody comprises either two conventional heavy chains, and two light chains that form a single polypeptide comprising, from N-terminus to C-terminus, an N-terminal antigen binding domain; a lipid-binding domain (LBD); and a C-terminal antigen binding domain; or two conventional light chains, and two heavy chains that form a single polypeptide comprising, from N-terminus to C-terminus, an N-terminal antigen binding domain; a lipid-binding domain (LBD); and a C-terminal antigen binding domain. Figure 21 also depicts, in the bottom row, potential configurations of a lipebody drug conjugate, wherein the LBD is covalently fused to the C terminus of either the antibody variable heavy (VH) or antibody variable light (VL).
[0130] Optionally, there is provided a loopable protein (LP) comprising, from N-terminus to C-terminus: an N-terminal antigen-binding domain; a plurality of amphipathic alpha helix domains; and a C-terminal antigen-binding domain.
[0131] Optionally, upon lipid association, N-terminal antigen binding domain and C-terminal antigen binding domain move closer to each other, enhancing the avidity of the loopable protein to its target antigen(s). By “avidity” is meant the accumulated strength of multiple affinities of individual non-covalent binding interactions, such as between the loopable protein and its target antigens, and is commonly referred to as functional affinity. Avidity differs from affinity, which describes the strength of a single interaction. However, because individual binding events increase the likelihood of occurrence of other interactions (i.e., increase the local concentration of each binding partner in proximity to the binding site), avidity should be thought of as the combined effect of all affinities participating in the biomolecular interaction.
[0132] In the loopable protein, the N-terminal antigen binding domain has the same amino acid sequence as the C-terminal antigen binding domain; or the N-terminal antigen binding domain and C-terminal antigen binding domain have different amino acid sequence. In the loopable, the N-terminal antigen binding domain and the C-terminal antigen binding domain may bind to the same antigen or a different antigen. In the loopable protein, the N-terminal antigen binding domain and the C-terminal antigen binding domain may be devoid of their binding activity while in lipid-free conformation and only regain their binding activity when brought in proximity (less than 2 nm) to each other after adding lipids.
[0133] In one aspect of any of the embodiments, described herein is a loopable protein (LP) comprising, from N-terminus to C-terminus: an N-terminal antibody variable heavy (VH) domain; at least one lipid-binding domain (LBD) that is, optionally, an amphipathic alpha helix domain or a plurality of amphipathic alpha helix domains; and a C-terminal variable light (VL) domain. Upon lipid association, VH and VL come in close proximity reconstituting the intact antigen binding paratope and forming a scFv-like lipebody (sL) (see Figure 4).
[0134] In one aspect of any of the embodiments, described herein is a loopable protein (LP) comprising, from N-terminus to C-terminus: an N-terminal antibody variable heavy 1 (VH1) domain followed by a short linker (4-8 amino acids), followed by a variable light 2 (VL2) domain; at least one lipid-binding domain (LBD) that is, optionally, an amphipathic alpha helix domain ora plurality of amphipathic alpha helix domains; and a C-terminal antibody variable heavy 2 (VH2) domain followed by a short linker (4-8 amino acids), followed by a variable light 1 (VL1) domain. Upon lipid association, VH1 / VL1 pair and VH2 / VL2 pair come in close proximity reconstituting a diabody-like lipebody (dL) (see Figure 4).
[0135] In one aspect of any of the embodiments, described herein is a loopable protein (LP) comprising, from N-terminus to C-terminus: an antibody heavy chain (HC) domain followed by a linker; at least one lipid-binding domain (LBD) that is, optionally, an amphipathic alpha helix domain or a plurality of amphipathic alpha helix domains, wherein the loopable protein HC domain can form at least a disulfide bond with a complementary antibody light chain (LC) domain (see Figure 21).
[0136] In one aspect of any of the embodiments, described herein is a loopable protein (LP) comprising, from N-terminus to C-terminus: an antibody light chain (LC) domain followed by a linker; at least one lipid-binding domain (LBD) that is, optionally, an amphipathic alpha helix domain or a plurality of amphipathic alpha helix domains, wherein the loopable protein LC domain can form at least a disulfide bond with a complementary antibody heavy chain (HC) domain (see Figure 21).
[0137] In some embodiments of any of the aspects, the LBD with secondary amphipathicity comprises an ApoA-l derived polypeptide; ApoE derived polypeptide; ApoJ derived polypeptide; at least one alpha helical polypeptide with secondary amphipathicity or a repeat thereof; or at least one repeat of the sequence ZXZPPP (SEQ ID NO: 10) wherein Z is any hydrophobic residue and X is any hydrophilic residue. In some embodiments of any of the aspects, the alpha helical polypeptide has a sequence selected from the group consisting of: (LKKLLK)n repeat (SEQ ID NO: 11); (LEK)n repeat; DFLKAFYDKVAEKFKEAAPDWFKAFYDKVAEKFKEAF (SEQ ID NO: 12);LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 13); KLALRLALKAFKAALKLA (SEQ ID NO: 14); RLALDLALRAFKAAWKLA (SEQ ID NO: 15); ELAWDLAFEALDAELKLD (SEQ ID NO: 16); FLKLLKKFLKLFKKLLKLF (SEQ ID NO: 17); WLKLLKKWLKLWKKLLKL (SEQ ID NO: 18); LLKFLKRLLKLLKDLWKLL (SEQ ID NO: 19); WEAAFAEALAEAWAEHLAEALAEAVEALAA (SEQ ID NO: 20); WEAKLAKALAKALAKHLAKALAKALKACEA (SEQ ID NO: 21);RAFARALARALKALARALKALAR (SEQ ID NO: 55); GLFEALLELLESLWELLLEA (SEQ ID NO: 22); KLLKLLLKLWKKLLKLLK (SEQ ID NO: 23); DWLKAFYDKVAEKLKEAF ((SEQ ID NO: 24);DWFKAFYDKLAEKFKEAF (SEQ ID NO: 78); and DWFKAFYDKVAEKFKEAF (SEQ ID NO: 25).
[0138] In some embodiments of any of the aspects, the LBD is designed to wrap around the lipid bilayer twice so that it interacts with the lipid’s acyl chains in both leaflets of the bilayer. Thewrapping of LBD is stabilized by one or more of the following interactions; hydrophobic, ionic, hydrogen bonds, disulfide bonds and van der Waals forces (see Figure 5).
[0139] In some embodiments of any of the aspects, at least one cysteine residue is placed near the N terminus of LBD and another cysteine residue is placed near the C terminus of LBD. After lipid association, the LBD changes its conformation, so that it brings the two cysteine in proximity to enable disulfide bond formation (see Figure 5). The disulfide bond stabilizes the lipebody structure and ensure that the antigen-binding domains are in proximity.
[0140] In some embodiments of any of the aspects, leucine zipper peptides are placed near the N and C termini between antigen binding domains and LBD to facilitates intramolecular dimerization and stabilization of the lipid binding conformation of LBD (wrapping twice) (see Figure 5). In some embodiments of any of the aspects, leucine-zipper peptides are placed within the LBD. In addition to facilitating intramolecular dimerization, the secondary amphipathicity in leucine zippers provides structural stability and promotes lipid association. In some embodiments of any of the aspects, the leucine-zipper has a sequence selected from the group consisting of: bZIP-(LEIRAAFLRQRNTALRTEVAELEQEVQRLENEVSQYETRY - SEQ ID NO: 56); bZIP+ (LEIEAAFLERENTALETRVAELRQRVQRLRNRVSQYRTRY- SEQ ID NO: 57);LEIEAAFLERENTALETRVAELRQRVQRLRNRVSQYRTRY- SEQ ID NO: 58;MKQLEDKVEELLSKNYHLENEVARLKKLVGER - SEQ ID NO: 59;LTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAA - SEQ ID NO: 60;RIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQ- SEQ ID NO: 61 ;AQAAEKERQRRNELKRSFFALRDQIPELENNEKAPKWILKK- SEQ ID NO: 62;TQETRDQEVQELQSVRQALEQQLKQFQQLLQQ - SEQ ID NO: 63;IRKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALK - SEQ ID NO: 64; KRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMTHVSNG - SEQ ID NO: 65;DKHSDEYKIRRERNNIAVRKSRDKAKRRNQEM -SEQ ID NO: 66;NRKVSKQYETLSDSLRKRKEVNESRVRKLVAAQ - SEQ ID NO: 67; or EIAALEKIAALEKIAALEKIAALEK- SEQ ID NO: 68.
[0141] In some embodiments of any of the aspects, the protein further comprises a cap sequence near the C or the N-terminal. The cap can be cleaved at the action site to expose the antigen-binding domains. For example, a TME (Tumor Microenvironment)-cleavable linker can be placed between the cap peptide and antigen-binding domain. The cap-linker can be designed to be cleaved by factors enriched in the TME, such proteases (e.g., matrix metalloproteinases [MMPs], cathepsins), low pH conditions (acidic microenvironment), reductive conditions (elevated glutathione [GSH] concentrations), hypoxia-induced enzymes. In some embodiments of any of the aspects, the cap-linker has a sequence selected from the group consisting of: Protease-sensitive (MMP):GPLGVRG (SEQ ID NO: 26) or PLGLAG (SEQ ID NO: 27); Cathepsin-sensitive: Val-Cit or FRRG (SEQ ID NO: 28); or Redox-sensitive: Disulfide-containing peptide (Cys-XXXX-Cys) where X is any amino acid (SEQ ID NO: 29). In some embodiments, the cap peptide is designed to interact electrostatically or hydrophobically with amino acid residues within the antigen-binding site (paratope), quenching (masking) its binding activity until cleavage occurs in the tumormicroenvironment (TME) or intended action site. In some embodiments of any of the aspects, the cap peptide has a sequence selected from the group consisting of: EKEEVKDL (SEQ ID NO: 30); EDEDEDED (SEQ ID NO: 31); EKDKDEEK (SEQ ID NO: 32); EKLLDLLE (SEQ ID NO: 33);FFWGGFF (SEQ ID NO: 34); or WELLEQKW (SEQ ID NO: 35).
[0142] In some embodiments of any of the aspects, the protein has the sequence of any of SEQ ID NOs: 36-54 or 80-85.
[0143] In one aspect of any of the embodiments, described herein is a lipebody comprising: a phospholipid bilayer; and a looped protein looped around the bilayer, wherein the looped protein comprises: an N-terminal antigen-binding domain; and at least one lipid-binding domain (LBD) that is, optionally, an amphipathic alpha helix domain or a plurality of amphipathic alpha helix domains, and a C-terminal antigen-binding domain.
[0144] In some embodiments of any of the aspects, the lipid bilayer diameter is greater than about 5 nm. In some embodiments of any of the aspects, the diameter is greater than about 10 nm. In some embodiments of any of the aspects, the diameter is greater than about 30 nm. In some embodiments of any of the aspects, the diameter is about 50 nm.
[0145] In one aspect of any of the embodiments, described herein is a method of making a lipebody as described herein, the method comprising: contacting the loopable protein with lipids (step a). In some embodiments of any of the aspects, the lipids are solubilized in detergent. In other embodiments of any of the aspects, the lipids are solubilized in buffer without detergent. In some embodiments of any of the aspects, step a occurs at a temperature of from about 0 °C to about 37 °C. In some embodiments of any of the aspects, step a occurs at a temperature of from about 0 °C to about 42 °C. In some embodiments of any of the aspects, the molar ratio of loopable protein to lipids is from about 1 :40 to about 1 :4500. In some embodiments of any of the aspects, the molar ratio of loopable protein to lipids is from about 1 :40 to about 1 :4500; and a lipid bilayer is formed. In some embodiments of any of the aspects, the molar ratio of loopable protein to lipids is from about 1 :40 to about 1:4500; and lipid bilayer wrapped by loopable protein stabilized by intramolecular disulfide bonds are formed. In some embodiments of any of the aspects, the molar ratio of loopable protein to lipids is from about 1 :40 to about 1 :4500; and lipid bilayer wrapped by loopable protein stabilized by intramolecular hydrophobic and electrostatic interactions are formed. In some embodiments of any of the aspects, dialysis or hydrophobic beads are used to remove detergent and initiate the lipebody assembly.
[0146] In some embodiments of any of the aspects, the lipid bilayer assembles into spherical, discoidal or elliptical shape.
[0147] In some embodiments of any of the aspects, the lipebody further comprises a cargo, optionally, a therapeutic payload, covalently or non-covalently associated with the lipebody, wherein said payload is selected from the group consisting of: small PD-11 molecule drugs, peptides, oligonucleotides, siRNA, or protein toxins.
[0148] In some embodiments of any of the aspects, the lipebody comprises a lipid bilayer stabilized by a lipid binding domain, and wherein the therapeutic payload is incorporated into the lipid bilayer via passive loading, detergent exchange, or active gradient loading.
[0149] In some embodiments of any of the aspects, the lipebody can be used alone or in combination with other therapeutic agents such as immune checkpoint inhibitor for enhanced efficacy.
[0150] Brief Description of the Drawings
[0151] The present invention is described with reference to the accompanying drawings in which:
[0152] Figure 1 depicts schematic representations of the conventional antibody and a lipidpeptide conjugate (lipebody), wherein the lipid-binding domain (LBD) is looped twice around a spherical lipid bilayer; the N-terminal antigen binding domain is adjacent to the N-terminal end of a a lipid binding peptide (loopable protein) and the C-terminal antigen binding domain is adjacent the C-terminal end of the loopable protein;
[0153] Figure 2 depicts schematic representations of a conventional antibody-drug conjugate (ADC) and a lipebody-drug conjugate (LDC), wherein the lipid-binding domain (LBD) is looped twice around a spherical lipid bilayer in which the drug is dispersed; the N-terminal antigen binding domain is adjacent to the N-terminal end of the loopable protein and the C-terminal antigen binding domain is adjacent to the C-terminal end of the loopable protein;
[0154] Figure 3 depicts, at the top, from left to right, first and second general domains (outlines) of the loopable proteins that are used for making lipebodies, wherein the first general outline, the N-terminal antigen binding domain is an N-terminal scFvand the C-terminal antigen binding domain is a C-terminal scFv and, in the second general outline, the N-terminal antigen binding domain is an N-terminal scFv and the C-terminal antigen binding domain includes first and second C-terminal scFvs and, for each general outline, the conformation, in the absence of lipids, of the loopable proteins are schematically represented below the respective linear loopable proteins, and, for each general outline, the loopable proteins, in the presence of lipids, undergo conformational changes after contacting lipids, bringing the N and C termini into close proximity (represented, at the bottom, under the respective conformations in the absence of lipids);
[0155] Figure 4 depicts schematic representations, from left to right in the top row, of a conventional antibody, a scFv-like lipebody (sL), and a diabody-like lipebody (dL), and from left to right in the bottom row, of a scFv, a scFv-like lipebody-drug conjugate (sLDC), and a diabody-like lipebody-drug conjugate (dLDC);
[0156] Figure 5 depicts schematic representations of the lipid-binding domain stabilized by one or more of the following interactions; leucine zipper, electrostatic interactions, mixture (from left to right in the top row); and disulfide bonds, hydrogen bonds, and hydrophobic interactions (from left to right in the bottom row); wherein the interacting amino acids are strategically placed within the LBD sequence so that they come in proximity as the LBD changes conformation in the presence of lipids (upon contacting lipids);
[0157] Figure 6 depicts the design of a lipid-binding domain of a lipid-peptide conjugate termed LP30, including the amino acid sequence of an LP30 peptide (6A), a diagram illustrating the predicted intramolecular interactions between the different helices (6B), wheel diagrams illustratingtwo potential configurations of the LP30 peptide in the presence of lipids (after contacting lipids) (6C);
[0158] Figure 7 depicts the design of a first modification of LP30 (wherein the 5” region of LP30 is replaced with A22 peptide; SDS-PAGE analysis of purified first modification of LP30 (the 5” region of LP30 is replaced with A22 peptide) (7A, left) and Western blot analysis using primary anti-His antibody (7A, right) wherein both SDS-PAGE and Western blot confirm the correct size of the protein; whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein in the presence of lipids (after contacting lipids) (7B) wherein the predicted secondary amphipathic helices are highlighted in different colors and labeled with a number; X, X” orX’” wherein X is a number from 1-10; the amino acid sequence of the first modification of the LP30 protein (7B) wherein N-terminal of a His tag is MGSS (SEQ ID NO: 69) incorporating a few amino acids (in this case, MGSS) before a His tag to improve accessibility to the His tag during purification and the N terminal His tag is followed by a TEV cleavage site that is ENLYFQG (SEQ ID NO: 70) or ENLYFQS (SEQ ID NO: 71), and an A22 peptide (SEQ ID 72: VLDLFRELLNELLEALKQKLK) is inserted at the center of the LP30 protein between helices 4” and 6”;
[0159] Figure 8 depicts the design of a second modification of the LP30 (wherein helices 4, 6, 4”, 6”, 4”’ and 6”’ have been deleted), demonstrating SDS-PAGE analysis of purified protein (8A, left) and Western blot analysis using primary anti-His antibody (8A, right), wherein both SDS-PAGE and Western blot confirm the correct size of the protein, whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein in the presence of lipids (after contacting lipids) (8B), wherein the predicted secondary amphipathic helices are highlighted in different shades and labeled with a number X, X” or X’” where X is a number from 1-10; and an amino acid sequence of the protein (8C);
[0160] Figure 9 depicts the design of a third modification of the LP30 (wherein helix 5” has been deleted) demonstrating SDS-PAGE analysis of purified protein (A, left) and Western blot analysis using primary anti-His antibody (9A, right) wherein both SDS-PAGE and Western blot confirm the correct size of the protein, whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein after contacting lipids (9B), and an amino acid sequence of the protein (9C);
[0161] Figure 10 depicts the design of a fourth modification of the LP30 (wherein helices 2, 3, 7, 2”, 3”, 7”, 2”’, 3”’, 7”’ have been deleted) demonstrating SDS-PAGE analysis of purified protein (10A, left) and Western blot analysis using primary anti-His antibody (10A, right) wherein both SDS-PAGE and Western blot confirm the correct size of the protein, whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein after contacting lipids (10B); and an amino acid sequence of the protein (10C);
[0162] Fig. 11 depicts a fifth modification of the design of the LP30 (wherein helices 2, 3, 7, 2”, 3”, 7”, 2”’, 3’”, 7”’, 4, 6, 4”, 6”, 4”’, 6’” have been deleted), demonstrating SDS-PAGE analysis of purified protein (11 A, left) and Western blot analysis using primary anti-His antibody (11 A, right)wherein both SDS-PAGE and Western blot confirm the correct size of the protein, whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein after contacting lipids (11B); and an amino acid sequence of the protein (11C);
[0163] Figure 12 depicts a sixth modification of the design of the LP30 (wherein helices 5, 5”’ have been deleted and helices A22, A22’” have been inserted) demonstrating SDS-PAGE analysis of purified protein 12A, whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein after contacting lipids (12B); and an amino acid sequence of the protein (12C);
[0164] Figure 13 depicts a seventh modification of the design of the LP30 (H1 S / C and H5” E / C, wherein H1 refers to helix 1 where S is mutated to C, H5” refers to second helix 5 where E is mutated to C); a wheel diagram illustrates a potential configuration of the protein after contacting lipids and disulfide bond formation between helix 1 and helix 5” (left); and an amino acid sequence of the protein (right), wherein two mutations; S4 / C (S at position 4 of helix 1 is replaced by a C) and E257 / C (E at position 257 is replaced by C) are highlighted in black;
[0165] Figure 14 depicts an eighth modification of the design of the LP30 (with entire replacement of helices 1 and 5” with a Leucine zipper 1 , 5” demonstrating SDS-PAGE analysis of purified protein (14A) whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein after contacting lipids and the formation of leucine zipper between helices 1 and 5” (14B); and an amino acid sequence of the protein with leucine zipper highlighted in black;
[0166] Figure 15 depicts a modification of the design of the LP30 (Leucine zipper N and C) wherein the leucine zipper components are attached to the free ends of the N and C-termini demonstrating SDS-PAGE analysis of purified protein (15A, left) and Western blot analysis using primary anti-His antibody (15A, right) whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; a wheel diagram illustrating a potential configuration of the protein after contacting lipids and formation of leucine zipper between the N and C termini (15B); and an amino acid sequence of the protein;
[0167] Figure 16 depicts the design of an A22-LP11 protein demonstrating SDS-PAGE analysis of purified protein (16, left) whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; and an amino acid sequence of the protein (16, right);
[0168] Figure 17 depicts the design of an A22-LP11 alternating protein demonstrating SDS-PAGE analysis of purified protein (17A, left) and Western blot analysis using primary anti-His antibody (17A, right) wherein both SDS-PAGE and Western blot confirm the correct size of the protein, whereby the protein was produced using E. coli expression system and purified using Ni-NTA resin; and an amino acid sequence of the protein (17B) wherein the A22 sequence PVLDLFRELLNELLEALKQKLK (SEQ ID NO: 76) and the various LP11 sequences (highlighted) are alternating therein;
[0169] Figure 18 depicts a ninth modification of the design of LP30 (wherein R / K / D / E are replaced with A demonstrating SDS-PAGE analysis of purified protein (18, left) whereby the proteinwas produced using E. coli expression system and purified using Ni-NTA resins; and an amino acid sequence of the protein with alanine highlighted;
[0170] Figure 19 depicts the design of HER2-LP30-HER2 demonstrating SDS-PAGE analysis of purified protein under reducing and non-reducing conditions (19, left); and an amino acid sequence of the protein (19, right) wherein the sequence starts with MGSS (SEQ ID NO: 69), followed by polyHis, followed by “AGGGS” (SEQ ID NO: 77), followed by a SMT3 solubility tag (highlighted in black) followed by a TEV cleavage site that is ENLYFQG (SEQ ID NO: 70), whereby the protein was expressed in CHO cells and purified with prism A affinity resin;
[0171] Figure 20 depicts production and characterization of B7H3-LP30-CD3 lipebody demonstrating SDS-PAGE analysis of the lipid-free purified protein (20A, left); an amino acid sequence of the protein (20B) wherein the sequence starts with MGSS (SEQ ID NO: 69) followed by polyHis, then followed by “AGGGS” (SEQ ID NO: 77); which is followed by an SMT3 solubility tag followed by a TEV cleavage site that is ENLYFQG (SEQ ID NO: 70); which is followed by a nanobody sequence that recognizes B7H3 (dark grey highlight), followed by LP30, followed by a nanobody sequence that recognizes CD3 (light grey highlight) whereby the protein was produced using E. coli expression system and purified using Ni-NTA resins; assembly of the B7H3-LP30-CD3 lipebody (20C) wherein POPC and POPG lipids, at 3:2 molar ratio, were added to the purified loopable protein and incubated at 4°C for 30 min before initiating detergent removal by dialysis or by non-polar polystyrene adsorbent beads (20C); size exclusion chromatography (SEC) analysis of the assembled B7H3-LP30-CD3 lipebody (20D, left); and SDS-PAGE analysis of the SEC main peak confirming the presence of B7H3-LP30-CD3 (20D, right);
[0172] Figure 21 depicts schematic representations of a conventional antibody and, in the top row, potential configurations of a lipebody, wherein the LBD is covalently fused to the C terminus of either the antibody variable heavy (VH) or antibody variable light (VL); which is a fusion protein, wherein the polypeptide chain contains both the VH (or VL) and the LBD immediately adjacent to it; which are “covalently” connected, as they are on the same polypeptide chain, and also “genetically fused” because their gene sequences are adjacent such that it is translated as a single polypeptide, in the bottom row, a conventional antibody drug conjugate and potential configurations of a lipebody drug conjugate, wherein the LBD is covalently fused to the C terminus of either the antibody variable heavy (VH) or antibody variable light (VL);
[0173] Figure 22 depicts schematic representations of two further potential configurations of lipebody, wherein the LBD is sandwiched between antibody variable heavy (VH) domain and a C-terminal antigen binding domain;
[0174] Figure 23 depicts schematic representations of a conventional antibody drug conjugate and, from left to right, potential configurations of lipebody, wherein the LBD is covalently fused to the C terminus of either the antibody variable light (VL) or the antibody variable heavy (VH), wherein the right-most configuration is a lipebody drug conjugate that corresponds to a conventional antibody fragment, wherein each lipebody comprises a loopable protein that is a fusion protein, where the polypeptide chain contains both the VH (or VL) and the LBD immediately adjacent to it, wherein they are “covalently” connected, as they are on the same polypeptide chain, wherein they are also“genetically fused” because their gene sequences are adjacent such that it is translated as a single polypeptide.;
[0175] Figure 24 depicts assembly and characterization of lipebodies demonstrating SDS-PAGE for HER2-LP30-HER2, LP30 (LZ 1, 5”) and CD276-LP30-CD3 lipebodies (24A); negativestain EM image of assembled LP30 (LZ 1, 5”) lipebody (24B); negative-stain EM images of assembled CD276-LP30-CD3 lipebody (24C); representative individual particles with densities protruding from the lipid surface, likely corresponding to the CD3 and CD276 domains (24C, bottom); and negative-stain EM for assembled HER2-LP30-HER2 lipebody (24D) wherein all assemblies were prepared using DMPC lipids;
[0176] Figure 25 depicts incorporation of MsbA protein into LP30 (LZ 1 ,5”) lipebody demonstrating size exclusion chromatography of assembled LP30 (LZ 1, 5”) incorporating MsbA protein, performed using Superose 6 Increase 10 / 300 GL column (25A) and SDS-PAGE analysis confirming co-elution of with lipebody in the F1 peak, indicating successful assembly (25B);
[0177] Figure 26 depicts immunofluorescence images (24h treatment) of CAF-S5 RFP reporter cells showing TGF-01 -induced fibroblast activation wherein nuclei are stained with DAPI (blue), and RFP signal (red) marks activated fibroblasts with TGF-01 + LP30 (1 ,5”) without drug (left) and TGF-p1 + drug-loaded LP30(1,5”) (right) wherein decreased RFP signal in the drug-loaded lipebody indicates suppression of fibrosis, wherein scale bar is 50 pm;
[0178] Figure 27 depicts both empty LP30 (1 , 5”) and LP (1 ,5”) containing polymyxin B which were incubated with buffer spiked with endotoxin for 45 minutes at 37°C whereby, after removing the lipebodies, the remaining amounts of LPS were quantified using LAL chromogenic endotoxin assay kit;
[0179] Figure 28 depicts effects of exatecan-loaded (TZ-H)+(TZ-L-LP30) formulations on SK-BR-3 cell viability demonstrating dose-response curves comparing exatecan-loaded (TZ-H)+(TZ-L-LP30), trastuzumab deruxtecan (ADC), and free exatecan in SK-BR-3 human breast cancer cells (28A); cell viability at an equivalent small-molecule concentration of 2 pM (28B) wherein drug-free (TZ-H)+(TZ-L-LP30) was used as a control, wherein, for all treatments, doses were normalized to deliver an equivalent amount of exatecan whereby cell viability was assessed 72h post-treatment, wherein data are presented as mean ± SD (n = 5);
[0180] Figure 29 depicts effects of exatecan-loaded (TZ-H)+(TZ-L-LP30) formulations on murine 4T1.2 cell viability demonstrating dose-response curves comparing exatecan-loaded (TZ-H)+(TZ-L-LP30), trastuzumab deruxtecan (ADC), and free exatecan in 4T1.2 breast cancer murine cells (29A); cell viability at an equivalent small-molecule concentration of 2 pM wherein drug-free (TZ-H)+(TZ-L-LP30) was used as a control, wherein, for all treatments, doses were normalized to deliver an equivalent amount of exatecan, whereby cell viability was assessed 72 h post-treatment wherein data are presented as mean ± SD (n = 5);
[0181] Figure 30 depicts engineering of a pH-triggered leucine zipper switch for controlled LP30 (LZ 1,5”) lipebody cargo release, demonstrating anamino acid sequence of the LP30 (LZ 1,5”) highlighting the leucine zipper peptides at positions 1 (N terminal) and 5’ (30A); an amino acid sequence of the leucine zipper peptide at the N-terminus, with heptad positions indicated (30B) wherein the lower schematic shows an example sequence in which histidine residues are introducedat selected e / g positions to create a pH-sensitive leucine zipper; and wherein, upon endosomal acidification, protonation of histidine residues disrupts electrostatic interactions within the leucine zipper, destabilizing the switch and triggering cargo release wherein the table at the bottom summarizes key advantages of lipebody compared with ADC (30C).
[0182] Figure 31 depicts cell viability using a colorimetric Cell Proliferation Kit I (MTT) of a A549 human lung adenocarcinoma epithelial cell model derived from alveolar basal epithelial cells, wherein A549 cells do express CD276 (B7-H3), but the level is typically moderate andvariable depending on culture conditions and passage;
[0183] Figure 32 depicts cell viability using a colorimetric Cell Proliferation Kit I (MTT) of a 769-P human clear cell renal cell carcinoma (ccRCC) model derived from a primary kidney tumor, tumor, wherein these cells exhibit loss of the von Hippel-Lindau (VHL) tumor suppressor, resulting in constitutive stabilization of hypoxia-inducible factors (HIFs) and upregulation of angiogenic pathways, including VEGF signaling, whereby 769-P cells are particularly well suited for evaluating kinase inhibitors such as sorafenib that target RAF and VEGF receptor pathways;
[0184] Figure 33 depicts effect of bispecific lipebody (CD276-LP30-CD3) on T cell-mediated cytotoxicity against A549 lung cancer cells wherein a killing assay was performed to quantify the number of remaining CD276-expressing A549 cells after co-culture with primary human T cells in the presence of the bispecific lipebody, wherein cells were monitored at 2 and 20 h after co-culture at an effector-to-target (E:T) ratio of 1:5 and, after 20 h, increased cell death, indicated by propidium iodide staining (dead cells, red), was observed in CD276-positive A549 cells, but not in CD276-negative cells;
[0185] Figure 34 depicts SDS-PAGE of (TZ-H) + (TZ-L-LP11) (34A); SDS-PAGE of (TZ-H) + (TZ-L-LP30) (34B), wherein both proteins were expressed in CHO cells and purified using protein A column;
[0186] Figure 35 depicts a schematic illustration of the assembly of (TZ-H) + (TZ-L-LP11) and (TZ-H) + (TZ-L-LP30) lipebodies, wherein lipebody (TZ-H) + (TZ-L-LP30) assembled into 15 or 30 nm depending on the protein to lipid ratio, and wherein the lipebody can incorporate a variety of cargoes, including small molecules and mRNA;
[0187] Figure 36 depicts a negative-stain EM of (TZ-H) + (TZ-L-LP30) (36A) and a negativestain EM of (TZ-H)+ (TZ-L) (36B);
[0188] Figure 37 depicts transfection of SK-BR-3 human breast cancer cells with (TZ-H) + (TZ-L-LP30) lipebody encapsulating mRNA encoding Green Fluorescent Protein (GFP); and
[0189] Figure 38 depicts characterization of lipid-peptide conjugates comprising an active agent, including methods of incorporating the active agents into the lipid-peptide conjugates, loading of the active agents, and release kinetics of the active agnets.
[0190] Detailed description of the invention
[0191] The present invention relates to methods of making lipebodies which permit previously unachievable simplicity for making antibody-like and ADC-like molecules and achieve high drugloading capacity. This new approach to lipebody construction involves the use of loopable proteinsthat change their conformation upon lipid association to enable the formation of a lipid bilayer. The LBD domain of the loopable protein can wrap around the lipid bilayer at least twice. The change in LBD conformation results in bringing the N and C termini to close proximity and, in some designs, reconstitution of antigen-binding domain(s). Antigen-binding domains can be intact or split among the N and C termini. Provided herein are loopable proteins, lipebodies comprising such proteins, and methods of producing these lipebodies.
[0192] Described herein are lipebodies and the loopable proteins used to construct these lipebodies. As used herein, “lipebody” refers to antibody-like molecules associated with lipids. The lipids are belted by the LBD part of the loopable protein. The LBD comprises amphipathic alpha helices which provide a hydrophobic surface next to the acyl chain of the phospholipid bilayer and an external hydrophilic surface that enhances its water solubility.
[0193] In one aspect of any of the embodiments, described herein is a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antigen-binding domain; at least one amphipathic alpha helix domain; and a C-terminal antigen-binding domain.
[0194] In one aspect of any of the embodiments, described herein is a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antigen-binding domain; a plurality of amphipathic alpha helix domains; and a C-terminal antigen-binding domain.
[0195] In one aspect of any of the embodiments, described herein is a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antigen-binding domain; at least one cysteine residue; a plurality of amphipathic alpha helix domains; at least one cysteine residue; and a C-terminal antigen-binding domain.
[0196] In one aspect of any of the embodiments, described herein is a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antigen-binding domain; leucine zipper peptide; a plurality of amphipathic alpha helix domains; a leucine zipper peptide; and a C-terminal antigen-binding domain.
[0197] As used herein, “loopable protein” refers to a protein which its LBD provides a hydrophobic environment, and the LBD’s exterior circumference forms a hydrophilic environment enhancing its water solubility. This LBD can accommodate a phospholipid bilayer within the interior circumference. The N and C termini of LBD can be covalently linked to each other utilizing at least one cysteine near each terminus of LBD. In some embodiments of any of the aspects, the N and C termini of LBD can be non-covalently linked utilizing two complementary leucine zipper peptides a and b, one near each terminus of LBD.
[0198] As used herein, “lipid binding domain (LBD) having secondary amphipathic character” refers to a domain comprising a continuous amphipathic alpha helix, e.g., an alpha helix with a face which is hydrophobic / non-polar and a second face which is hydrophilic / polar. In some embodiments, the lipid binding domain (LBD) having secondary amphipathic character” comprises an amphipathic alpha helix domain. In some embodiments, a loopable protein can comprise a plurality of amphipathic alpha helix domains, e.g., multiple domains separated by non-helical sequences.Several exemplary amphipathic alpha helix domains are provided herein. By way of non-limiting example, an amphipathic alpha helix domain can comprise an ApoA-l polypeptide or repeats thereof; ApoJ polypeptide or repeats thereof; ApoE polypeptide or repeats thereof; at least one alpha helicalpolypeptide with secondary amphipathicity or a repeat thereof; at least one amphipathic proline-rich polypeptide or a repeat thereof; or at least one repeat of the sequence ZXZPPP (SEQ ID NO: 10); wherein Z is any hydrophobic residue (e.g., any of A, I, L, F, V, P,W, M, Y and G) and X is any hydrophilic residue (e.g., any of R, K, D, E, Q, N, H, S,T, or C). A given amphipathic alpha helix domain and / or loopable protein can comprise a combination of any of the specific sequences and domains described herein.
[0199] As used herein, “secondary amphipathic character” refers to amphipathicity existing in the secondary structure of a polypeptide, e.g., the polar residues are found on one face of the secondary structure and the nonpolar residues are found on the opposite face of the secondary structure.
[0200] ApoA-l (e.g., NCBI Gene ID: 335), also referred to as ApoA1 , refers to the major protein component of high-density lipoprotein (HDL) in plasma, which also serves a cofactor for lecithin cholesterol acyl transferase (LCAT). The sequences for ApoA-l are known fora number of species, e.g., human ApoA-l mRNA (e.g., NCBI Ref Seq: NM_000039.2) and protein (e.g., NCBI Ref Seq: NP_000030.1; SEQ ID NO: 20) sequences. The native ApoA-1 protein comprises a 43 residue N-terminal globular domain and a 200 residue C-terminal lipid binding domain (e.g., residues 68-267 of SEQ ID NO: 73) which forms an amphipathic alpha helix. As used herein, “ApoA-l polypeptide” refers to a polypeptide comprising at least one repeat or segment derived from the amphipathic lipid-binding domain of ApoA-1 sufficient to mediate lipid association.
[0201] ApoJ (also known as Clusterin, e.g., NCBI Gene ID: 1191) refers to a glycoprotein broadly expressed in various tissues and biological fluids. ApoJ is involved in lipid transport, cell apoptosis, complement inhibition, and functions as a molecular chaperone. Sequences for ApoJ are well-known in multiple species, including human ApoJ (e.g., NCBI RefSeq: NP_001822.3; SEQ ID NO: 21). The native ApoJ protein comprises an N-terminal alpha-chain and a C-terminal beta-chain generated by proteolytic cleavage of a precursor protein, linked by disulfide bonds, and characterized by amphipathic a-helical domains critical for lipid binding and interaction with hydrophobic molecules. As used herein, an “ApoJ polypeptide” refers to a polypeptide comprising at least one repeat or segment derived from the amphipathic lipid-binding domain of ApoJ sufficient to mediate lipid association.
[0202] Apolipoprotein E (ApoE) is a multifunctional protein (NCBI Gene ID: 348), expressed abundantly in liver, brain, and other tissues, involved primarily in lipid metabolism and cholesterol transport. ApoE exhibits amphipathic alpha-helical domains responsible for binding and transporting hydrophobic lipid molecules within circulating lipoproteins. The sequences for ApoE are well-established across multiple species, including human ApoE mRNA (e.g., NCBI RefSeq:NM_000041.4) and protein sequences (e.g., NCBI RefSeq: NP_000032.1; UniProt ID: P02649; SEQ ID NO: 22). As used herein, an "ApoE polypeptide" refers to a polypeptide comprising at least one repeat or segment derived from the amphipathic lipid-binding domain of ApoE, typically corresponding to residues involved in lipid binding (e.g., residues 130-150, 141-150, or other established amphipathic helical segments).
[0203] In some embodiments of any of the aspects described herein, an alpha helical polypeptide with secondary amphipathicity can have a sequence selected from the group consistingof: (LKKLLK)n repeat (SEQ ID NO: 11); (LEK)n repeat; DWFKAFYDKLAEKFKEAF (SEQ ID NO: 78); DFLKAFYDKVAEKFKEAAPDWFKAFYDKVAEKFKEAF (SEQ ID NO: 12); KLALRLALKAFKAALKLA (SEQ ID NO: 14); RLALDLALRAFKAAWKLA (SEQ ID NO: 15); ELAWDLAFEALDAELKLD (SEQ ID NO: 16); FLKLLKKFLKLFKKLLKLF (SEQ ID NO: 17); WLKLLKKWLKLWKKLLKL (SEQ ID NO: 18); LLKFLKRLLKLLKDLWKLL (SE ID NO: 19); WEAAFAEALAEAWAEHLAEALAEAVEALAA (SEQ ID NO: 20); WEAKLAKALAKALAKHLAKALAKALKACEA (SEQ ID NO: 21);RAFARALARALKALARALKALAR (SEQ ID NO: 55); GLFEALLELLESLWELLLEA (SEQ ID NO: 22); KLLKLLLKLWKKLLKLLK (SEQ ID NO: 23); DWLKAFYDKVAEKLKEAF (SEQ ID NO: 24);DWFKAFYDKVAEKFKEAF (SEQ ID NO: 25); or variants thereof.
[0204] Alpha helical polypeptides with secondary amphipathicity are readily identified by one of skill in the art, e.g., the Helical Wheel Prediction algorithm available at rzlab.ucr.edu / scripts / wheel / can be used to characterize the secondary amphipathicity of a query polypeptide sequence.Secondary amphipathic peptides are described further in the art at, e.g., S. Gottschalk et al., Gene Ther. 1996; 3: 448-457; T. Niidome et al. Bioconjugate Chem. 1999; 10(5): 773-780); B. Chung et al., J. Bio. Chem. 1985; 260:10256-10262; and H. Kariyazono et al. J. Pept. Sci. 2016; 22: 116-122.
[0205] In some embodiments, a cap peptide is included near the N orC termini of the loopable protein. The cap peptide is specifically designed to interact non-covalently with amino acid residues within the adjoining antigen-binding site (paratope), thereby reversibly quenching or masking antigen-binding activity. For example, a cap peptide can be included next to anti-CD3 scFv sequence. The interactions between the cap peptide and the anti-CD3 scFv can include electrostatic (ionic), hydrogen bonds, hydrophobic, or combinations thereof, thus preventing unintended systemic immune cell activation. In some embodiments, the cap peptide is joined to the scFv via a linker specifically designed to be cleaved by tumor microenvironment (TME)-enriched factors such as matrix metalloproteinases (MMPs), cathepsins, acidic pH conditions, or elevated glutathione concentrations. Following linker cleavage at the intended action site, the cap peptide dissociates, resulting in exposure and activation of the previously masked anti-CD3 scFv binding domain. In certain embodiments, the cap peptide sequences capable of interacting with and reversibly masking anti-CD3 antigen-binding domains are selected from the group consisting of: EKEEVKDL (SEQ ID NO: 30); EDEDEDED (SEQ ID NO: 31); EKDKDEEK (SEQ ID NO: 32); EKLLDLLE (SEQ ID NO: 33); FFWGGFF (SEQ ID NO: 34); or WELLEQKW (SEQ ID NO: 35). These peptides contain strategically arranged charged residues (e.g., glutamic acid [E], aspartic acid [D], lysine [K]) and hydrophobic residues (e.g., leucine [L]), facilitating strong but reversible binding through electrostatic interactions and / or hydrophobic complementarity with anti-CD3 scFv residues. Examples of lipebody embodiments containing cap peptide include (SEQ ID NOS: 53, 54).
[0206] Affinity tags can be used for, e.g., affinity purification or to immobilize a protein to a desired substrate or surface. A number of affinity tags and their binding partner ligands are well known in the art and are described, e.g., Lichty et al. Protein Expr Purif 200541 :98-105; Zhao et al. J Analytical Methods in Chemistry 2013; Kimple et al. Current Protocols in Protein Science 2004 36:939:9.1-9.9.19; and Giannone et al. Methods and Protocols “Protein Affinity Tags" Humana Press 2014. Non-limiting examples of affinity tags can include His tags, Flag tags, or Strep tags.
[0207] In one aspect of any of the embodiments, described herein is a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antibody variable heavy (VH); a plurality of amphipathic alpha helix domains; and a C-terminal variable light (VL) domain. Upon lipid association, VH and VL come in closer proximity reconstituting the antigen binding paratope of an scFv-like lipebody (sL).
[0208] In one aspect of any of the embodiments, described herein is a loopable protein comprising, from N-terminus to C-terminus: an N-terminal antibody variable heavy 1 (VH1) followed by a short linker (4-8 amino acids), followed by a variable light 2 (VL2) domains; a plurality of amphipathic alpha helix domains; and a C-terminal antibody variable heavy 2 (VH2) followed by a short linker (4-8 amino acids), followed by a variable light 1 (VL1) domains. Upon lipid association, VH1 / VL1, VL2 / VH2 pairs come in close proximity reconstituting two antigen binding paratopes and diabody-like lipebody (dL). A short linker between the VH and VL domains is critical fordL proper assembly. The short linker restricts pairing of neighboring VH and VL and instead promotes pairing among complementary variable domains from each end of loopable protein.
[0209] Illustrative examples of linkers used to connect various domains of lipebody include glycine polymers (G)n; glycine-serine polymers (Gi-sSi-5)n, where n is an integer of at least one, two, three, four, or five; glycine-alanine polymers; alanine-serine polymers; and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured, and therefore may be able to serve as a neutral tether between domains of the proteins described herein. Glycine accesses significantly more phi-psi space than alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). The ordinarily skilled artisan will recognize that design of a protein in particular embodiments can include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure to provide for a desired lipebody structure. Other exemplary linkers include, but are not limited to the following amino acid sequences: GGG; DGGGS (SEQ ID NO: 1); TGEKP (SEQ ID NO: 2) (see Liu et al., PNAS 5525-5530 (1997)); GGRR;(GGGGS)n wherein = 1, 2, 3, 4 or 5 (SEQ ID NO: 3) (see Kim et al., PNAS 93, 1156-1160 (1996); EGKSSGSGSESKVD (SEQ ID NO: 4) (see Chaudhary et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070); KESGSVSSEQLAQFRSLD (SEQ ID NO: 5) (see Bird et al., 1988, Science 242:423-426), GGRRGGGS (SEQ ID NO: 6); LRQRDGERP (SEQ ID NO: 7); LRQKDGGGSERP (SEQ ID NO: 8); and LRQKD(GGGS)2 ERP (SEQ ID NO: 9). Alternatively, flexible linkers can be rationally designed using a computer program capable of modeling both lipid-binding sites and the peptides themselves.
[0210] In some embodiments of any of the aspects, the shape of the bilayer can be guided by the ratio of lipids to loopable protein used during the assembly. In some embodiments of any of the aspects, the shape of the bilayer can be directed by the structure of the loopable protein.
[0211] In some embodiments of any of the aspects, the loopable protein has the sequence of any of SEQ ID NOs: 36-54.
[0212] In one aspect of any of the embodiments, described herein is a nucleic acid encoding a loopable protein as described herein. In one aspect of any of the embodiments, described herein is avector comprising a nucleic acid encoding a loopable protein as described herein. It is important to note that the loopable protein may be translated as a single protein.
[0213] In some embodiments of any of the aspects, the diameter of the lipebody bilayer is greater than about 5 nm. In some embodiments of any of the aspects, the diameter of the lipebody bilayer is greater than 10 nm. In some embodiments of any of the aspects, the diameter of the lipebody bilayer is greater than about 15 nm. In some embodiments of any of the aspects, the diameter of the lipebody bilayer is greater than 20 nm. In some embodiments of any of the aspects, the diameter of the lipebody bilayer is greater than about 50 nm.
[0214] The lipebody described herein comprise lipids and phospholipids. As used herein, the term "phospholipid" refers to phosphatidic acids, phosphoglycerides, and phosphosphingolipids. Phosphatidic acids include a phosphate group coupled to a glycerol group, which may be mono- or diacylated. Phosphoglycerides (or glycerophospholipids) include a phosphate group intermediate an organic group (e.g., choline, ethanolamine, serine, inositol) and a glycerol group, which may be mono- or diacylated. Phosphosphingolipids (or sphingomyelins) include a phosphate group intermediate an organic group (e.g., choline, ethanolamine) and a sphingosine (non-acylated) or ceramide (acylated) group. It will be appreciated that, in certain embodiments, the phospholipids useful in the compositions and methods of the invention include their salts (e.g., sodium, ammonium). For phospholipids that include carbon-carbon double bonds, individual geometrical isomers (cis, trans) and mixtures of isomers are included.
[0215] Representative phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, and phosphatidic acids, and their lysophosphatidyl (e.g., lysophosphatidylcholines and lysophosphatidylethanolamine) and diacyl phospholipid (e.g., diacylphosphatidylcholines, diacylphosphatidylethanolamines, diacylphosphatidylglycerols, diacylphosphatidylserines, diacylphosphatidylinositols, and diacylphosphatidic acids) counterparts.
[0216] The acyl groups of the phospholipids may be the same or different. In certain embodiments, the acyl groups are derived from fatty acids having C10-C24 carbon chains (e.g., acyl groups such as lauroyl, myristoyl, palmitoyl, stearoyl or oleoyl groups). Representative diacylphosphatidylcholines (i.e., 1 ,2-diacyl-sn-glycero-3-phosphocholines) include distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dilinoleoylphosphatidylcholine DLPC), palmitoyloleoylphosphatidylcholine (POPC), palmitoyllinoleoylphosphatidylcholine, stearoyllinoleoylphosphatidylcholine stearoyloleoylphosphatidylcholine, stearoylarachidoylphosphatidylcholine, didecanoylphosphatidylcholine (DDPC), dierucoylphosphatidylcholine (DEPC), dilinoleoylphosphatidylcholine (DLOPC), dimyristoylphosphatidylcholine (DMPC), myristoylpalmitoylphosphatidylcholine (MPPC), myristoylstearoylphosphatidylcholine (MSPC), stearoylmyristoylphosphatidylcholine (SMPC), palmitoylmyristoylphosphatidylcholine (PMPC), palmitoylstearoylphosphatidylcholine (PSPC), stearoylpalmitoylphosphatidylcholine (SPPC), and stearoyloleoylphosphatidylcholine (SOPC).
[0217] Representative diacylphosphatidylethanolamines (i.e., 1 ,2-diacyl-sn-glycero-3-phosphoethanolamines) include dioleoylphosphatidylethanolamine (DOPE),dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), dilauroylphosphatidylethanolamine (DLPE), dimyristoylphosphatidylethanolamine (DMPE), dierucoylphosphatidylethanolamine (DEPE), and palmitoyloleoylphosphatidylethanolamine (POPE).
[0218] Representative diacylphosphatidylglycerols (i.e., 1 ,2-diacyl-sn-glycero-3-phosphoglycerols) include dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dierucoylphosphatidylglycerol (DEPG), dilauroylphosphatidylglycerol (DLPG), dimyristoylphosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), and palmitoyloleoylphosphatidylglycerol (POPG).
[0219] Representative diacylphosphatidylserines (i.e., 1 ,2-diacyl-sn-glycero-3- phosphoserines) include dilauroylphosphatidylserine (DLPS), dioleoylphosphatidylserine (DOPS), dipalmitoylphosphatidylserine (DPPS), and distearoylphosphatidylserine (DSPS).
[0220] Representative diacylphosphatidic acids (i.e., 1 ,2-diacyl-sn-glycero-3-phosphates) include dierucoylphosphatidic acid (DEPA), dilauroylphosphatidic acid (DLPA), dimyristoylphosphatidic acid (DMPA), dioleoylphosphatidic acid (DOPA), dipalmitoylphosphatidic acid (DPPA), and distearoylphosphatidic acid (DSPA).
[0221] Representative phospholipids include phosphosphingolipids such as ceramide phosphoryllipid, ceramide phosphorylcholine, and ceramide phosphorylethanolamine.
[0222] In some embodiments of any of the aspects, the phospholipid can be a native lipid extract. Additional lipids that may be used as provided herein include lipids of the Archaea and other extremophilic microorganisms (see de Rosa M. et al. Biosensors & Bioelectronics).
[0223] In some embodiments of any of the aspects, the phospholipid can be a headgroup modified lipid, e.g., alkyl phosphates (e.g. 16:0 Monomethyl PE; 18:1 Monomethyl PE; 16:0 Dimethyl PE; 18:1 Dimethyl PE; 16:0 Phosphatidylmethanol; 18:1 Phosphatidylmethanol; 16:0 Phosphatidylethanol; 18:1 Phosphatidylethanol; 16:0-18:1 Phosphatidylethanol; 16:0 Phosphatidylpropanol; 18:1 Phosphatidylpropanol; 16:0 Phosphatidylbutanol; and 18:1 Phosphatidylbutanol); MRI imaging reagents (e.g.14:0 PE-DTPA (Gd); DTPA-BSA (Gd); 16:0 PE-DTPA (Gd); 18:0 PE-DTPA (Gd); bis(14:0 PE)-DTPA (Gd); bis(16:0 PE)-DTPA (Gd); and bis(18:0 PE)-DTPA (Gd)); chelators (e.g., 14:0 PE-DTPA (Gd); DTPA-BSA (Gd); 16:0 PE-DTPA (Gd); 18:0 PE-DTPA (Gd); bis(14:0 PE)-DTPA (Gd); bis(16:0 PE)-DTPA (Gd); and bis(18:0 PE)-DTPA (Gd)); glycosylated lipids (e.g., 18:1 Lactosyl PE); pH sensitive lipids (e.g., N-palmitoyl homocysteine; 18:1 DGS; 16:0 DGS; and DOBAQ); antigenic lipids (e.g., DNP PE and DNP Cap PE); adhesive lipids (e.g., 16:0 DG Galloyl); and functionalized lipids (e.g., 16:0 PA-PEG3-mannose; 16:0 Caproylamine PE; 18:1 Caproylamine PE; 16:0 MPB PE; 18:1 MPB PE; 16:0 Ptd Ethylene Glycol; 18:1 Ptd Ethylene Glycol; 16:0 Folate Cap PE; 16:0 Cyanur PE; 16:0 Biotinyl PE; 18:1 Biotinyl PE; 16:0 Biotinyl Cap PE; 16:0 Cyanur Cap PE; 18:1 Biotinyl Cap PE; 16:0 Dodecanoyl PE; 18:1 Dodecanyl PE; 16:0 Glutaryl PE; 18:1 Glutaryl PE; 16:0 Succinyl PE; 18:1 Succinyl PE; 16:0 PDP PE; 18:1 PDP PE; 16:0 Ptd Thioethanol; 18:1 Dodecanylamine PE; 16:0 Dodecanylamine PE; 16:0 PE MCC; 18:1 PE MCC; 16:0 hexynoyl PE; and 16:0 azidocaproyl PE.
[0224] In some embodiments of any of the aspects, the lipebody of the invention can comprise one type of phospholipid. In other embodiments of any of the aspects, the lipebody of the invention can comprise two or more different phospholipids. In some embodiments of any of the aspects, thelipebodies of the invention can comprise two different phospholipids. In some embodiments of any of the aspects, the lipebodies of the invention can comprise three different phospholipids. In some embodiments of any of the aspects, the lipebody of the invention can comprise four different phospholipids.
[0225] In some embodiments of any of the aspects described herein, the lipebody can further comprise a molecule of interest, e.g., hydrophobic small molecules, hydrophobic drugs, hydrophilic small molecules, hydrophobic drugs, peptides, siRNA, ASO and toxins. In some embodiments of any of the aspects described herein, the lipebody described herein can be or be utilized as a drug delivery vehicle.
[0226] In some embodiments of any of the aspects described herein, the lipebodies with or without a therapeutic payload, achieve therapeutic effects by specifically targeting proteins involved in disease processes through multiple mechanisms including; blocking ligand-receptor interactions to inhibit signaling pathways, inducing receptor internalization and degradation, directly mediating cell death, or apoptosis, modulating immune responses, such as by blocking immune checkpoints in cancer or cytokine receptors in autoimmune diseases, and neutralizing pathogens or toxins in infectious diseases.
[0227] In some embodiments of any of the aspects, the loopable protein is in solution prior to adding lipids. In some embodiments of any of the aspects, the loopable protein is in solution at a concentration of 1 uM to about 1 mM prior to contacting lipids.
[0228] In some embodiments of any of the aspects, the lipids are solubilized in detergent. Exemplary detergents can include but are not limited to Decyl p-D-maltopyranoside, Deoxycholic acid, Digitonin, n-Dodecyl p-D-glucopyranoside, n-Dodecyl p-D-maltoside, N-Lauroylsarcosine sodium salt, Sodium cholate, Undecyl p-D-maltoside, Triton X-100, CHAPS, 5-Cyclohexylpentyl p-D-maltoside, n-dodecyl phosphatidylcholine and n-octyl-p-d-glucoside.
[0229] In some embodiments of any of the aspects, the phospholipids are mixed with hydrophobic small molecules ordrugs in presence or absence of detergent.
[0230] In some embodiments of any of the aspects, the lipid contacting and the subsequent detergent removal occurs at a temperature of from about 0°C to about 37°C. In some embodiments of any of the aspects, the lipid contacting and the subsequent detergent removal second step occurs at a temperature of from 0°C to 42°C.
[0231] In some embodiments of any of the aspects, the ratio of loopable protein to phospholipids is from about 1 :20 to about 1 :4500.
[0232] Examples
[0233] The present invention; including the use of these lipebodies for, e.g., therapeutics, drug delivery, diagnostics, and imaging; is further described with reference to the following non-limiting examples:
[0234] Example 1
[0235] Near-infrared (NIR) fluorescence imaging of tumors and inflammatory sites
[0236] The lipebodies offer significant advantages for diagnostics and biomedical imaging due to their unique properties, such as enhanced stability, structural uniformity, and the capacity to incorporate diverse membrane-associated biomolecules. In imaging applications, lipebodies can be readily functionalized with imaging moieties, including fluorescent dyes, quantum dots, or radioactive isotopes, creating effective contrast agents. The compact size (typically in the range of~5-15 nm diameter) and well-defined structure facilitate improved tissue penetration and reduced nonspecific interactions, thereby enhancing imaging sensitivity and specificity.
[0237] For example, fluorescently labeled anti EGFR-lipebody can serve as sensitive probes to image EGFR-overexpressing tumors using fluorescence microscopy or positron emission tomography (PET). Fluorescent label or radioisotope (e.g., Cy5, IRDye800, 64Cu) can be mixed with lipids during lipebody assembly, or added after lipebody assembly. One or more of anti-EGFR domain(s) can be chemically fused to the N- and / or or C- termini of the loopable protein.
[0238] Other receptors that can be utilized for cancer molecular imaging using lipebody include, but are not limited to; Human epidermal growth factor receptor 2 (HER2), Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptors (SSTRs), Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Activation Protein (FAP), and CXCR4 (C-X-C Chemokine Receptor 4).
[0239] Lipebodies targeting the following receptors; TSPO, CXCR4, VCAM-1 , integrins, folate or receptor beta, can offer valuable tools for diagnosing and monitoring inflammation in diseases such as autoimmune disorders, neuroinflammation, cardiovascular disease, and infection.
[0240] Example 2
[0241] Design and production of a monospecific lipebody
[0242] Human epidermal growth factor receptor 2 (HER2), also known as ERBB2 or Neu, refers to a transmembrane receptor tyrosine kinase belonging to the epidermal growth factor receptor (EGFR) family, which includes HER1 (EGFR), HER2, HER3, and HER4 (see Yarden, Y, Nat Rev Mol Cell Bioy, 127-137, 2001). HER2 is encoded by the human HER2 gene (NCBI Gene ID: 2064; RefSeq: NM_004448.4, protein RefSeq: NP_004439.2) and plays a crucial role in normal cellular growth and differentiation processes. In multiple cancer types, particularly breast, gastric, ovarian, lung, colorectal, and pancreatic cancers, HER2 can become amplified or overexpressed at levels significantly higher than normal tissues. Such overexpression of HER2 frequently correlates with aggressive tumor progression, increased metastatic potential, poor prognosis, and decreased overall patient survival. Specifically, HER2 overexpression occurs in approximately 20-30% of breast cancers, wherein it serves as a critical driver of oncogenic signaling, leading to enhanced tumor cell proliferation, survival, angiogenesis, and metastasis. Moreover, HER2 amplification is clinically associated with increased tumor aggressiveness, higher recurrence rates, resistance to standard chemotherapy, and overall decreased patient survival.
[0243] The oncogenic signaling activity of HER2 is mediated primarily through receptor dimerization (homodimerization or heterodimerization with other ErbB family members such as EGFR [HER1 ], HER3, and HER4) followed by subsequent activation of intracellular signaling pathways, including Ras-Raf-MEK-ERK and PI3K-AKT-mTOR cascades. Persistent activation of these signaling pathways promotes tumor cell proliferation, inhibits apoptosis, facilitates cellular invasion, and enhances metastatic dissemination.
[0244] Given its central role in tumor biology, HER2 has emerged as a critical therapeutic target for cancer treatment. Targeted therapeutic approaches directed against HER2 include monoclonal antibodies (e.g., trastuzumab, pertuzumab), antibody-drug conjugates (e.g., trastuzumab emtansine [Kadcyla], trastuzumab deruxtecan [Enhertu]), and tyrosine kinase inhibitors (e.g., lapatinib, neratinib). Clinical implementation of HER2-targeting therapeutics has substantially improved patient outcomes, significantly reduced recurrence and improving survival rates for HER2-positive cancers. Despite these advances, clinical challenges remain, including inadequate tumor penetration of large antibody-based agents.
[0245] The present invention demonstrates that it is possible to construct monospecific HER2-LP30-HER2 lipebody (SEQ ID NO 51). The sequence comprises, from N-terminus to C-terminus: an N-terminal His tag; a SMT3 solubility tag; HER2 binding domain; LP30 lipid binding domain; and a HER2 binding domain. The sequence was cloned onto a pCDNA3.4 vector and expressed in CHO cells. The protein was purified with Prism A affinity resin. SDS-PAGE shows a band around the correct molecular weight (131 KDa).
[0246] Example 3
[0247] Design and production of a bispecific lipebody
[0248] B7-H3 (CD276) is a transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules, which are known fortheir roles in immune regulation (see Chapoval et al., Nat. Immunol., 2(3):269-274 (2001); and Leitner et al., Eur. J. Immunol., 39(7):1754-1764 (2009). The B7-H3 gene (NCBI Gene ID: 80381 , RefSeq: NM_001024736.2, Protein RefSeq:NP_001020907.2) encodes a type I transmembrane protein that has been implicated in modulating both immune responses and tumor progression. B7-H3 is highly overexpressed in a wide range of solid tumors, including breast, lung, prostate, pancreatic, colorectal, ovarian, and brain cancers (e.g., glioblastoma, medulloblastoma, and neuroblastoma). Notably, B7-H3 is minimally expressed in normal tissues, making it a promising tumor-associated antigen (TAA) for targeted cancer therapy. Overexpression of B7-H3 has been associated with tumor aggressiveness, metastasis, poor prognosis, and resistance to therapy. Mechanistically, B7-H3 promotes immune evasion by suppressing T-cell proliferation, cytokine production, and cytotoxic activity, thereby inhibiting antitumor immune responses. Additionally, B7-H3 is involved in enhancing tumor cell migration, invasion, angiogenesis, and epithelial-to-mesenchymal transition (EMT), further contributing to tumor progression.
[0249] Given its tumor-specific overexpression and role in immune suppression, B7-H3 has become a promising therapeutic target for cancer treatment. Several strategies have been developed to target B7-H3, including monoclonal antibodies (e.g., enoblituzumab), antibody-drug conjugates (ADCs, e.g., MGC018), chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies, and immune checkpoint inhibitors. Among these approaches, antibody-drug conjugates (ADCs) have demonstrated promising preclinical and early clinical data, leveraging B7-H3’s high tumor specificity to deliver cytotoxic payloads while minimizing off-target toxicity. B7-H3-targeted CAR-T cell therapies have also shown potential, particularly in refractory pediatric neuroblastoma and glioblastoma models, highlighting their utility in difficult-to-treat malignancies.
[0250] T cell engagers are a promising class of immunotherapeutic agents designed to recruit and activate cytotoxic T cells (CD8+) to selectively eliminate tumor cells. These bispecific molecules typically feature dual-binding domains: one targeting a tumor-associated antigen (TAA) on cancer cells and the other engaging CD3 on T cells to induce immune synapse formation and tumor cell lysis. Given the high expression of B7-H3 in multiple solid tumors and its limited expression in normal tissues, B7-H3-targeting T cell engagers represent an attractive therapeutic strategy for enhancing anti-tumor immunity.
[0251] The present invention demonstrates that it is possible to construct and produce B7H3-LP30-CD3 T cell engager lipebody. For example, a B7-H3-specific binding domain (e.g., a fragment derived from an anti-B7-H3 monoclonal antibody, scFv, nanobody ora peptide), and a CD3-binding domain (e.g., a fragment derived from an anti-CD3 monoclonal antibody, scFv, nanobody or a peptide) are linked via LP30 lipid binding domain (SEQ ID NOS: 52-54).
[0252] Expression of B7H3-LP30-CD3 in E. coli expression system: The loopable sequence comprises, from N to C terminus: N-terminal His8 tag; SMT3 solubility tag, followed by TEV site, B7-H3-specific binding domain; LP30; and CD3-binding domain. The DNA plasmid (in pET-11b) was transformed into BL21 (DE3) competent E. coli cells. Three liters cell cultures were grown at 37 °C, 200 rpm in Luria broth (LB) medium supplemented with 100 pg / ml ampicillin, and expression was induced with 0.5 mM IPTG at an OD600 of 0.8 for 3 hours at 37 °C or 16 hours at 18 °C. Cells were harvested by centrifugation (5000xg, 20 minutes, 4°C) and cell pellets were stored at -80°C.
[0253] Purification of B7H3-LP30-CD3 loopable protein: Cell pellets were resuspended in lysis buffer (20 mM Tris-HCI, pH 8.0, 200 mM NaCI, 1% Triton X-100) and lysed by microfluidizer or sonication on ice. Lysate was centrifuged (32,000xg, 45 minutes, 4 °C) and the supernatant was filtered and loaded onto Ni2+-NTA column. The column was washed with lysis buffer, then with buffer A (20 mM Tris, pH 8.0, 200 mM NaCI). Ni-NTA resin column was then successively washed with 15 column volume (CV) (15 successive washes where each wash is 1 column volume; column volume could be between 1-20 mis (or more)) of the following: buffer A + 1% Triton X-100, buffer A + 25 mM sodium cholate, buffer A, and buffer A + 20 mM imidazole. B7H3-LP30-CD3 was eluted with buffer A + 500 mM imidazole. TEV can be used to cleave His8 and solubility SMT3 tag if desired.
[0254] Reconstitution of B7H3-LP30-CD3 lipebody. Loopable protein :lipid molar ratio of 1 :300 was used to assemble ~14 nm lipebody. Lipids (POPC:POPG 3:2 molar ratio solubilized in sodium cholate detergent) and the loopable protein were incubated on ice for 30 minutes. After incubation, detergent was removed by the addition of Bio-beads SM-2 or dialysis overnight at 4°C. The lipebodypreparation was filtered through 0.45-pm nitrocellulose-filter tubes and further purified by sizeexclusion chromatography while monitoring the absorbance at 280 nm on a Superdex 200 column equilibrated in 20 mM Tris HCI, pH 7.5, 200 mM NaCI. Fractions corresponding to the size of lipebody were collected and concentrated. The purity of lipebody preparation was checked using SDS-PAGE (see Figure 20).
[0255] Example 4
[0256] Design of a trispecific lipebody
[0257] It is possible to construct and produce a tri-specific CD38-CD3-CD28 T cell engager lipebody for targeting CD38-expressing hematologic cancers. For example, a CD38-specific binding domain (e.g., a fragment derived from an anti-CD38 monoclonal antibody, scFv, nanobody or a peptide), a CD3-binding domain (e.g., a fragment derived from an anti-CD3 monoclonal antibody, scFv, nanobody or a peptide); and a CD28-binding domain (e.g., a fragment derived from an anti-CD28 monoclonal antibody, scFv, nanobody or a peptide) are linked via any of LBD described herein, for example, SEQ ID NOS: 36-50.
[0258] Mechanism of action of CD38-CD3-CD28 trispecific lipebody. The lipebody binds CD38 on tumor cells while simultaneously engaging CD3 on T cells, redirecting T cells to kill CD38+ cancer cells. The CD28 engagement provides an additional costimulatory signal, enhancing T cell activation and persistence in the tumor microenvironment. The tri-specific design allows more potent and sustained T cell responses compared to conventional bispecific antibodies.
[0259] It is possible to construct and produce trispecific BCMA-CD3-Albumin-binding lipebody for multiple myeloma. BCMA (CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17)) is a B cell maturation antigen that is overexpressed in malignant plasma B cells. The trispecific format, integrates BCMA targeting, CD3 T cell activation, and albumin-binding for prolonged half-life.
[0260] To construct the lipebody, a BCMA-specific binding domain (e.g., a fragment derived from an anti-BCMA monoclonal antibody, scFv, nanobody or a peptide), a CD3-binding domain (e.g., a fragment derived from an anti-CD3 monoclonal antibody, scFv, nanobody or a peptide); and Albumin binding domain (e.g. nanobody ora peptide) are linked via any LBD described herein, for example, SEQ ID NOS: 36-50. An albumin binding domain may increase the circulatory half-life.
[0261] The expression, purity, and assembly of different lipebodies was assessed and the results are given in Table 1.
[0262] Table 1: Constructs expressed, including their expression levels, purification assessment, and ability to assemble into lipebody.Name Expression Purity Assembled to lipebody after adding lipids LP30 (replace 5" with A22 Peptide) High expression > 85% YesLP30 (d 4, 6, 4", 6", 4"', 6"') Medium expression < 50% Noand some degradationLP30 (d 5") High expression > 80% Yes LP30 (d 2, 3, 7, 2", 3", 7", 2"' , 3"', High expression > 90% Yes 7"')LP30 (d 2, 3, 7, 2", 3", 7", 2"' , 3"', High expression > 85% ND 7"', 4, 6, 4", 6", 4"', 6"')LP30 (d 5, 5 " ') insert (A22, A22'") High expression > 90% Yes LP30 (H1 S / C and H5" E / C) Low expression and < 20% Notoo much degradationLP30 (Leucine Zipper 1 , 5") High expression > 90% Yes LP30 (Leucine Zipper N and C) High expression > 85% Yes A22-LP11 Too much degradation < 50% No A22-LP11 alternating Low expression and < 20% Notoo much degradationLP30 (R / K / D / E replaced with A) High expression and < 60% NDtoo much degradationLP100 Too much degradation < 20% No B7H3-LP30-CD3 High expression > 80% Yes HER2-LP30-HER2 Medium expression > 80% Yes (TZ-H) + (TZ-L-LP11) Medium expression > 90% Yes (TZ-H) + (TZ-L-LP30) High expression > 90% Yes (TZ-L) + (H-TZ-LP11) Medium expression Modifying the ND heavy chain withLP11 blocksProtein A bindingand thereforeinterferes withpurification(TZ-L) + (H-TZ-LP30) Medium expression Modifying the ND heavy chain withLP30 blocksProtein A bindingand thereforeinterferes withpurification
[0263] Example 5
[0264] Combination of lipebody-drug conjugate (LDC) and an immune checkpoint inhibitor for enhanced anti-tumor efficacy
[0265] The LDC component delivers a cytotoxic payload selectively to tumor cells, inducing immunogenic cell death (ICD) and releasing tumor-associated antigens (TAAs) and danger-associated molecular patterns (DAMPs), which facilitate dendritic cell activation and T-cell priming. Concurrent administration of an immune checkpoint inhibitor (e.g., anti-PD-1, anti-PD-L1, oranti-CTLA-4 antibody) blocks immune suppressive pathways in the tumor microenvironment, thereby enhancing T-cell activation, infiltration, and persistence. This combination results in a synergistic therapeutic effect, wherein the LDC induces localized tumor cytotoxicity and immune activation, while the checkpoint inhibitor sustains and amplifies the adaptive anti-tumor immune response. The combined approach is particularly beneficial in immunologically "cold" tumors.
[0266] It is possible to combine HER2-LP30-HER2 (SEQ ID NO: 51) loaded with a topoisomerase I inhibitor (e.g. deruxtecan) with anti-PD-1 antibody (e.g., nivolumab or pembrolizumab) for the treatment of HER2-expressing cancers.
[0267] Upon binding to HER2-positive tumor cells, the lipebody releases deruxtecan, inducing immunogenic cell death (ICD) characterized by calreticulin exposure, ATP release, and HMGB1 secretion. These signals promote dendritic cell activation and enhance tumor antigen presentation. Administration of an anti-PD-1 antibody (e.g., nivolumab or pembrolizumab) blocks the interaction between PD-1 on T cells and PD-L1 on tumor cells or antigen-presenting cells, thereby reversing T-cell exhaustion and promoting T-cell activation, proliferation, and cytotoxicity. The combination results in a synergistic anti-tumor effect, wherein the LDC drives tumor cell killing and antigen release, while the PD-1 inhibitor amplifies and sustains the resulting adaptive immune.
[0268] In further embodiments, the combination therapy may be administered sequentially or concurrently, with dosing regimens optimized for safety and efficacy.
[0269] Example 6
[0270] Loading hydrophobic small molecules and drugs into lipebody using passive incorporation
[0271] In some embodiments, a hydrophobic small molecule is incorporated into the lipebody lipid bilayer through passive diffusion or solvent-assisted loading. Here is a specific example of small molecule:paclitaxel (hydrophobic chemotherapy drug), lipid: POPC, and loopable protein: B7H3-LP30-CD3 (SEQ ID NO 52) using loading method: dissolve paclitaxel in ethanol or DMSO at a concentration of 1-10 mg / mL; add paclitaxel solution to a lipid mixture (molar ratio of lipid:drug is 10:1) and evaporate solvent under vacuum to form a thin lipid film; rehydrate the film with a buffer solution (e.g., PBS, pH 7.4) containing B7H3-LP30-CD3 loopable protein so that the final molar ratio of protein :lipid :drug is 1 :300:30; sonicate or incubate at 4°C for 30 minutes to facilitate drug incorporation; and purify paclitaxal-loaded lipebody using size-exclusion chromatography (SEC).
[0272] Similarly, a variety of other hydrophobic drugs can be passively incorporated into a lipebody by embedding within the lipid bilayer due to their poor water solubility and high lipophilicity, to form a lipebody-drug conjugate (LDC). These include, but are not limited to: docetaxel, camptothecin and deruxtecan which are potent topoisomerase I inhibitors; etoposide, atopoisomerase II inhibitor. Other hydrophobic agents include curcumin, a natural polyphenol with anticancer properties; tamoxifen, an estrogen receptor modulator; and lipophilic retinoids such as fenretinide and bexarotene. Compounds like resveratrol, although not conventional chemotherapeutics, also demonstrate anticancer activity and can be incorporated for improved bioavailability. The passive loading of these agents into lipebody enhances their solubility, stability, and delivery efficiency in therapeutic applications.
[0273] Example 7
[0274] Loading amphiphilic small molecules via detergent exchange method
[0275] In some embodiments, an amphiphilic small molecule is incorporated into lipebodies using a detergent exchange method, which allows controlled insertion of the molecule into the lipid bilayer. Here is a specific example of small molecule: IR-780 (near-infrared fluorescent imaging agent), lipid: DMPC, and a loopable protein: LP30 (d5”) (SEQ ID NO: 39) using a loading method: solubilize DMPC lipids and IR-780 in DDM, Octyl glucoside, Triton X-100, or CHAPS detergent micelles; add LP30 (d5”) scaffold protein to DMPC / IR-780 mixture to achieve a protein: lipid :dye molar ratio of 1 :250:20; slowly remove detergent using Bio-Beads SM-2 resin or dialysis (22°C, 12 hours); keep the preparation in the dark away from light; and separate IR-780-loaded lipebody from free dye via SEC or ultrafiltration.
[0276] Other amphiphilic small molecules that can be loaded via detergent exchange include, but are not limited to: amphotericin B, tamoxifen, curcumin derivatives, ivermectin, resveratrol, artemisinin derivatives, chlorpromazine, dronabinol, rhodamine dyes, Dil and DiD lipophilic tracers, and quercetin. These molecules possess both hydrophobic and hydrophilic features, allowing them to partition into lipid bilayers during co-solubilization with detergents. This method enhances their incorporation into lipebodies, improving solubility, membrane interaction, and bioavailability for therapeutic or diagnostic applications
[0277] Applications include near-infrared (NIR) fluorescence imaging of tumors and inflammatory sites; and theranostic applications combining imaging and drug delivery.
[0278] Example 8
[0279] Loading hydrophilic small molecules into lipebody core
[0280] In some embodiments, hydrophilic small molecules are encapsulated into the aqueous core of lipebody, forming stable drug delivery vehicles. Here is a specific example of small molecule: Doxorubicin (water-soluble upto ~10 mg / mL); lipids: POPC and DSPC in a 3:2 molar ratio; and a loopable protein: HER2-LP30-HER2 (SEQ ID NO: 51) using a loading method: hydrate lipid film (that had been dried under nitrogen gas stream in a glass tube) with an ammonium sulfate (NH4)2SO4 gradient buffer (pH 5.0); add HER2-LP30-HER2 loopable protein and perform 3-5 freeze / thaw cycles or extrude through a 50 nm or smaller polycarbonate filter; incubate preformed lipebody withdoxorubicin at drug:lipid ratio = 1:10, adjust pH to neutral (pH 7.4) to trigger active drug loading into lipebody core, and remove unincorporated doxorubicin via dialysis or SEC.
[0281] Other hydrophilic small molecules that can be loaded into the aqueous core of lipebody include, but are not limited to, daunorubicin, vincristine, methotrexate, gemcitabine, 5-fluorouracil (5-FU), ascorbic acid (vitamin C), cisplatin, levodopa (L-DOPA), acyclovir, gentamicin, ampicillin, and hydrocortisone. These molecules are water-soluble and can be encapsulated either passively during lipebody formation or actively using ion or pH gradients, depending on their chemical properties. Their encapsulation enhances bioavailability, protects against degradation, and enables controlled release for therapeutic applications in cancer, infection, inflammation, and neurological disorders.
[0282] Applications include controlled release of doxorubicin for targeted cancer therapy; and reduction of cardiotoxicity through lipid-based drug encapsulation.
[0283] Example 9
[0284] Covalent drug conjugation to lipebodies
[0285] In some embodiments, small molecules are chemically conjugated to lipids in a lipebody. Here is a specific example of small molecule: methotrexate (MTX, folate analog chemotherapy drug; lipids: POPC and DSPE-PEG2000 in a 9:1 molar ratio; and a loopable protein: HER2-LP30-HER2 (SEQ ID NO: 51) using a conjugation method: activate methotrexate with N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC); react activated MTX with DSPE-PEG2000 amine-functionalized lipids at pH 8.0; incorporate POPC and MTX-DSPE-PEG2000 conjugate into lipebody via solvent exchange; and purify using ultrafiltration (MWCO (CO means cut off) 30 kDa).
[0286] Applications include passive and active targeting of cancer cells via folate receptor-mediated endocytosis; and extended circulation time with reduced systemic toxicity.
[0287] Example 10
[0288] Assessment of drug loading efficiency in lipebodies
[0289] In some embodiments, the drug loading efficiency of lipebody is assessed by quantifying the encapsulated or incorporated drug relative to the initial drug input. In one example, a fluorescent or absorbance-based method is used to measure the concentration of the drug within lipebodies following purification. Specifically, a hydrophobic small molecule such as paclitaxel, incorporated into B7H3-LP30-CD3 (SEQ ID NO: 52) is stabilized within a POPC lipebody using passive diffusion loading method. Post-loading, unincorporated paclitaxel is removed using size-exclusion chromatography (SEC) or ultrafiltration (MWCO 30 kDa filters). The encapsulated paclitaxel is then quantified using UV-Vis spectrophotometry (227 nm for paclitaxel) or high-performance liquid chromatography (HPLC) with a standard calibration curve. In additional embodiments, mass spectrometry (LC-MS / MS) may be employed for precise quantification, particularly for highly potent therapeutic agents.
[0290] Example 11
[0291] Assessment of drug release kinetics from lipebodies
[0292] In some embodiments, drug release studies are performed to evaluate the stability and controlled release properties of lipebodies-formulated therapeutics under physiological conditions. In one example, doxorubicin-loaded lipebodies are incubated in phosphate-buffered saline (PBS, pH 7.4) at 37°C, and drug release is monitored overtime using fluorescence spectroscopy (Ex / Em: 470 / 585 nm). In alternative embodiments, dialysis-based release assays are performed by placing drug-loaded lipebodies in dialysis membranes (MWCO 10 kDa) against release buffer, followed by periodic collection of dialysate samples. The concentration of released drug is measured using HPLC or UV-Vis spectrophotometry, and the cumulative drug release profile is plotted as a function of time. The release kinetics may be analyzed using mathematical models such as zero-order, first-order, or Korsmeyer-Peppas models to determine the release mechanism. In additional embodiments, enzyme-triggered release assays may be conducted wherein lipebodies are exposed to tumor microenvironment-specific enzymes (e.g., cathepsins, MMPs) to assess stimulus-responsive drug release behavior.
[0293] Example 12
[0294] Modulation of drug release and entrapment efficiency in lipebodies
[0295] In some embodiments, the drug release profile and entrapment efficiency of lipebodies are modulated by altering the lipid composition, LBD length, or linker chemistry. For instance, increasing the cholesterol content in lipebodies (e.g., POPC: cholesterol at a 3:1 molar ratio) enhances membrane rigidity, thereby reducing drug diffusion rates and enabling prolonged release. In alternative embodiments, incorporating charged lipids (e.g., POPG, 1 ,2-Dioleoyl-3-trimethylammonium propane (DOTAP)) enhances electrostatic interactions with oppositely charged drugs, leading to higher drug entrapment efficiency (DEE) and slower release kinetics. In some cases, PEGylated lipids (e.g., DSPE-PEG2000) can be introduced to modify the lipebody hydrodynamic size and circulation stability, influencing both drug retention and in vivo pharmacokinetics. Additionally, for stimuli-responsive drug release, biodegradable enzyme-cleavable lipids (e.g., phospholipids conjugated with MMP- or cathepsin-sensitive linkers) can be incorporated, allowing triggered drug release in tumor microenvironments. Further, LBD engineering (e.g., increasing the number of amphipathic peptides) increases lipebody diameter, which can accommodate higher drug loads while modulating drug partitioning dynamics within the lipid bilayer. In alternative embodiments, chemical conjugation strategies involving pH-sensitive or redox-responsive linkers (e.g., thiol-cleavable disulfide bonds) enable controlled drug release in response to tumor microenvironment conditions such as acidic pH or elevated glutathione levels. These approaches allow fine-tuning of drug loading capacity, entrapment efficiency, and release kinetics, optimizing lipebody-based drug formulations for targeted and sustained therapeutic delivery.
[0296] Example 13
[0297] Characterization of drug-loaded lipebodies
[0298] In some embodiments, drug-loaded lipebodies are characterized using physicochemical, structural, and functional assays to confirm drug entrapment, stability, and release kinetics. Dynamic light scattering (DLS) and zeta potential analysis are used to determine lipebody size distribution, polydispersity index (PDI), and surface charge, which influence stability and biodistribution.Transmission electron microscopy (TEM) and cryo-electron microscopy (cryo-EM) provide morphological confirmation of lipebody integrity and homogeneity, while small-angle X-ray scattering (SAXS) can be used to assess structural changes in the lipid bilayer upon drug incorporation. To quantify drug loading efficiency (DLE) and entrapment efficiency (DEE), high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), or UV-V is spectrophotometry is used to measure drug concentration before and after lipebody purification. Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) may be used to analyze drug-lipid interactions and phase behavior, ensuring that the drug remains stably incorporated. Additionally, fluorescence-based assays (e.g., Forster resonance energy transfer [FRET]) can be employed to study drug partitioning within the bilayer. Functional validation is performed by in vitro drug release studies, wherein lipebodies are subjected to buffer conditions mimicking physiological pH, temperature, and enzymatic environments, followed by real-time monitoring of drug release profiles using UV-Vis, HPLC, or fluorescence spectroscopy. These characterization techniques ensure that drug-loaded lipebodies exhibit optimized stability, controlled release, and enhanced bioavailability for therapeutic or diagnostic applications.
[0299] Example 14
[0300] Assembly and characterization of lipebodies
[0301] LP30 (LZ 1 , 5”) and CD276-LP30-CD3 proteins were recombinantly expressed in E. coli, while HER2-LP30-HER2 was expressed in CHO cells. The E. coli expressed proteins were purified using Ni-affinity followed by size-exclusion chromatography. HER2-LP30-HER2 was purified using Protein A affinity chromatography. Purity was assessed by SDS-PAGE.
[0302] DMPC lipid was dissolved in chloroform, dried under a nitrogen stream, and further desiccated under vacuum to form a thin lipid film. The lipid film was hydrated in 20 mM Tris, pH 8.0, 100 mM NaCI, 100 mM sodium cholate buffer. Purified lipebody proteins were then added at a protein-to-lipid ratio of approximately 1 :150. The mixtures were incubated at 22°C for 30 minutes followed by addition of Bio-beads or dialysis to enable spontaneous assembly. The assembled lipebodies were purified using size-exclusion chromatography to isolate assembled particles.Lipebody assembly and integrity were assessed by negative-stain EM to visualize particle morphology.
[0303] Example 15
[0304] Incorporation of MsbA protein into LP30 (LZ 1,5”) lipebody
[0305] MsbA protein was expressed recombinantly and purified in the presence of detergents such as DDM orTriton-X 100. POPG lipids were dissolved in chloroform, dried under nitrogen, and further desiccated under vacuum to form a thin lipid film. The lipid film was hydrated in 20 mM Tris, pH 8.0, 100 mM NaCI, 100 mM sodium cholate buffer. Purified LP30(LZ 1,5”) protein and detergent-solubilized MsbA were then mixed with the lipid at 1 :0.5:50 LP30(1 ,5”): MsbA: lipids molar ratios to promote co-assembly. Lipebody assembly was initiated by gradual detergent removal using dialysis or hydrophobic adsorption resin. The assembled MsbA-containing lipebody was subsequently purified by size-exclusion chromatography to separate properly assembled particles from free proteins and aggregates. Successful incorporation of MsbA into lipebody was confirmed by SDS-PAGE analysis showing co-elution of MsbA and LP30 (1 ,5”).
[0306] Example 16
[0307] Fibrosis activation
[0308] Fibrosis activation was monitored using RFP reporter cells, enabling visualization of the fibroblast-to-myofibroblast transition upon TGF-beta signaling stimulation. Cells were treated with TGF-01 (5 ng / mL) in the presence of LP30 (LZ 1 ,5”) lipebody without drug or TGF-01 plus drug-loaded lipebody (concentration of drug is 5 pM ) for 24 h. Lipebodies were assembled using DMPC lipids. Anti-fibrotic activity was quantified by measuring RFP fluorescence intensity; a decrease in red fluorescence in cells treated with drug-loaded lipebody indicated suppression of fibrosis.
[0309] Example 17
[0310] Macrophage-Targeted Polymyxin-loaded lipebody for Endotoxin Capture and Hepatosplenic Clearance
[0311] To enhance hepatosplenic clearance of polymyxin-loaded lipebody, the design can be optimized using modifications that promote efficient recognition and uptake by macrophages.First, mannose display on the lipebody surface enables targeting of the CD206 mannose receptor, which is highly expressed on Kupffer cells and splenic macrophages, facilitating rapid phagocytic uptake. Second, incorporation of phosphatidylserine into the lipid bilayer provides a natural “eat-me” signal that mimics apoptotic bodies, further promoting macrophage-mediated clearance through efferocytosis pathways.
[0312] Polymyxin-loaded lipebody could be further optimized by co-loading an antibiotic to provide dual activity against Gram-negative sepsis. In this design, polymyxin B incorporated into the lipebody would rapidly bind and neutralize circulating LPS, while the co-loaded antibiotic would suppress or kill the underlying bacterial source of endotoxin. This dual-function approach could combine endotoxin scavenging with antibacterial therapy, potentially reducing systemic inflammation while improving bacterial control. For lipebody loading, more hydrophobic antibiotics may partitionmore readily into the lipid bilayer, whereas hydrophilic antibiotics may require encapsulation strategies, or conjugation to achieve efficient co-delivery.
[0313] Polymyxin can be strategically incorporated into lipebody to serve not only as an endotoxin-neutralizing agent but also as a targeting ligand for Gram-negative bacteria. By exploiting its high affinity for LPS on the bacterial outer membrane, polymyxin enables lipebody to selectively bind and localize to bacterial surfaces. When co-loaded with an antibiotic, this designfacilitates localized drug delivery, increasing the effective concentration of the antibiotic at the site of infection while minimizing systemic exposure. In addition, polymyxin’s ability to disrupt the bacterial outer membrane can enhance permeability, thereby improving the intracellular access and efficacy of co-delivered antibiotics. This dual-function approach offers a promising strategy tocombine bacterial targeting, membrane permeabilization, and antibiotic delivery in a single nanotherapeutic platform.
[0314] Polymyxin B (PMB) was co-incubated with His-tagged pre-assembled LP30 (1 ,5”) lipebody composed of POPC:POPG at a 3:2 molar ratio and gently shaken for 45 min. Unbound PMB was removed using a 30 kDa desalting column. The resulting PMB-loaded lipebody was then incubated with LPS at 1 EU / mL for 45 min at 37°C. Following incubation, the mixture was loaded onto a Ni-NTA column to capture and remove His-tagged PMB-lipebody. The flow-through fraction, containing unbound LPS, was collected and analyzed using the Pierce Chromogenic Endotoxin Quantitation Kit according to the manufacturer’s protocol.
[0315] Example 18
[0316] Effects of exatecan-loaded (TZ-H)+(TZ-L-LP30) formulations on SK-BR-3 cell viability
[0317] Unlike the ADC, which plateaued at ~35% residual viability, drug-loaded lipebody may overcome key delivery bottlenecks, suggesting reduced reliance on HER2-mediated internalization and lysosomal payload release. Although SK-BR-3 cells are classified as HER2-high and relatively homogeneous, measurable cell-to-cell variability in HER2 expression and downstream functional response persists, which can contribute to incomplete cytotoxicity in ADC-based assays. These factors, together with constraints such as receptor saturation and limited internalization capacity, likely contribute to the observed ceiling in ADC-mediated killing.
[0318] The apparent increase in SK-BR-3 cell viability with higher doses of drug-free lipebody is most likely not a true proliferative effect but an artifact of the assay and / or a metabolic response. Lipid-based particles can enhance mitochondrial activity, alter redox states, or interfere with MTT readouts, leading to artificially elevated viability signals. Additionally, these formulations may provide lipids that transiently support cellular metabolism or membrane integrity. Together, these effects can produce a dose-dependent increase in apparent viability without a corresponding increase in cell number.
[0319] Example 19
[0320] 4T1 .2 cells are a highly metastatic murine breast cancer cell line derived from the parental 4T1 mammary carcinoma. These cells exhibit a triple-negative phenotype (ER- / PR- ZHER2-) and display aggressive growth, invasion, and a strong propensity for spontaneous metastasis to distant organs such as the lung, liver, and bone. Their rapid proliferation and robust metastatic behavior provide a stringent platform for assessing therapeutic efficacy, including drug delivery systems and cytotoxic agents.
[0321] As expected, 4T1.2 cells, which lack HER2 expression, show minimal sensitivity to trastuzumab deruxtecan (ADC), consistent with the requirement for HER2-mediated binding and internalization for efficient payload delivery. In contrast, lipebody-loaded exatecan demonstrates robust cytotoxicity in these cells, indicating effective receptor-independent uptake. Consequently, lipebody formulations may overcome key limitations of ADCs in target-negative or heterogeneous tumors, enabling broader activity across diverse cancer cell populations.
[0322] Smaller lipebody, such as (TZ-H)+ (TZ-L-LP11), may provide a practical strategy to balance receptor-independent cytotoxicity with improved selectivity by reducing nonspecific uptake in normal cells while enhancing tumor penetration and intratumoral distribution.
[0323] Example 20
[0324] Cell viability
[0325] Cell viability was assessed using a colorimetric Cell Proliferation Kit I (MTT) (11465007001 , Roche). Cells were seeded in 96-well plates (229196, CellTreat) at an appropriate density and incubated at 37 °C in a humidified atmosphere with 5% CO2to ensure proper attachment to the well plates. The following day, cells were treated with test formulations at the indicated concentrations, normalized to equivalent small-molecule doses where applicable. After 48h or 72 h of incubation at 37 °C in a humidified atmosphere with 5% CO2, The MTT assay was conducted according to the manufacturer’s protocol. In brief, MTT labeling reagent was added to each well and incubated for 4 h to allow formation of formazan crystals. And the crystals were dissolved in solubilization buffer to make homogeneous solution, enable to measure absorbance. Absorbance was measured at 570 nm using a microplate reader, with background correction at 630-690 nm. Cell viability was calculated as a percentage relative to untreated control wells. All experiments were performed with 3-5 replicates, and data are presented as mean ± SD. Differences between groups were analyzed by Welch’s t-test or unpaired One-way ANOVA with Tukey’s post hoc test. The p-value < 0.05 was considered statistically significant^ p<0.05, ** p<0.01 , *** p<0.001 , and **** p<0.0001).
[0326] Example 21
[0327] T cell engaging assay
[0328] T cell engaging assay was assessed using immunofluorescence. Tumor cells that expressing CD276 and control tumor cells that doesn't express CD276 were seeded in MatTek 8-well Cell Culture Slides (CCS-8) at an appropriate density and incubated at 37 °C in a humidified atmosphere with 5% CO2to ensure proper attachment to the well plates. Human CD8 T cell, isolated from PBMC was stained with 0.5pg / ml NHS-Flouresein (Thermo Scientific, 46409) for 15min at room temperature. The 500ng / ml of CD3-LP30-CD276 bispecific lipebody and the Fluorscein stained CD8 T cells were resuspended into cell culure slides with E:T ratio of 1 :5 where the tumor cells were initially incubated. After 2 and 20 h of co-culture at 37 °C in a humidified atmosphere with 5% CO2, the cells were stained with 1 pg / ml of propidium iodide (PI) to stain dead cells. The cellular behavior and viability was measured by brightfiled image and fluorescence microscopy respectively. All experiments were performed with 2 replicates.
[0329] Example 22
[0330] mRNA transfection
[0331] SK-BR-3 breast cancer cells were cultured in growth medium supplemented with fetal bovine serum and antibiotics. Cells (3000 cells per well) were seeded into multiwell plates and allowed to adhere overnight prior to treatment. mRNA-loaded (TZ-H)+(TZ-L-LP30) were added to the cells at 400 ng / well mRNA doses and incubated for 8 hrs to permit cellular uptake and intracellular delivery. Transfection efficiency was assessed by measuring expression of the green fluorescence protein (GFP) using fluorescence microscopy.
[0332] References1. Beck, A. et al., “Strategies and challenges for the next generation of antibody-drug conjugates”, Nature Reviews Drug Discovery, vol. 16, no. 5, pp. 315-337, May 2017.2. Chari, R.V.J. et al., “Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy”, Angewandte Chemie International Edition, vol. 53, no. 15, pp. 3796-3827, April 2014. 3. Hamblett, K.J. et al., “Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate” Clinical Cancer Research, vol. 10, no. 20, pp. 7063-7070, October 2004.4. Pillow, T.H. et al., “Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers” Chemical Science, vol. 8, no. 1 , pp. 366-370, January 2017.5. Lyon, R.P. et al., “Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index,” Nature Biotechnology, vol. 33, no. 7, pp.733-735, July 2015.6. Sun, M.M.C. et al., “Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides, "Bioconjugate Chemistry, vol. 16, no. 5, pp. 1282-1290, September 2005.7. Jain, N. et al., “Antibody-Drug Conjugates: Current Landscape and FutureDirections, "BioDrugs, vol. 36, no. 3, pp. 265-280, May 2022.8. Joubert, N. et al., “Antibody-drug conjugates: The last decade, "Pharmaceuticals, vol. 13, no.9, Article 245, September 2020.9. Lyon, R.P. et al., “Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates” mAbs, vol. 7, no. 2, pp. 204-211, March 2015. 10. Lu, J. et al., “Linkers Having a Crucial Role in Antibody-Drug Conjugates, "International Journal of Molecular Sciences, vol. 17, no. 4, Article 561, April 2016.11. Donaghy, H., “Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates,” mAbs, vol. 8, no. 4, pp. 659-671, May 2016.12. Thurber, G.M. et al., “Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance” Advanced Drug Delivery Reviews, vol. 60, no. 12, pp. 1421— 1434, August 2008.13. Loganzo, F. et al., “Mechanisms of resistance to antibody-drug conjugates” Molecular Cancer Therapeutics, vol. 15, no. 12, pp. 2825-2834, December 2016.14. Chau, C.H. et al., “Antibody-drug conjugates for cancer”, The Lancet, vol. 394, no. 10200, pp. 793-804, August 2019.15. Hock, M.B. et al., “Immunogenicity of antibody-drug conjugates: Bioanalytical methods and monitoring strategy for a novel therapeutic modality”, The AAPS Journal, vol. 17, no. 1 , pp.35-43, January 2015.16. Carrasco-Triguero, M. et al., “Immunogenicity assays for antibody-drug conjugates”, Bioanalysis, vol. 11, no. 17, pp. 1559-1572, September 2019.17. Xiang, L. et al., “Single-chain antibody fragments fused with toxins or payloads for targeted cancer therapy”, Journal of Hematology & Oncology, vol. 13, Article 152, 2020.18. Gottschalk, S., Sparrow, J. T., Hauer, J., Mergia, A., Woo, S. L. C., & Woo, S. L. (1996). "A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells." Gene Therapy, 3, 448-457.19. Niidome, T., Ohmori, N., Wada, A., Mihara, H., Hirayama, T., Aoyagi, H., & Katayama, Y.(1999). "Binding of cationic a-helical peptides to plasmid DNA and their gene delivery abilities." Bioconjugate Chemistry, 10(5), 773-780.20. Chung, B. H., Segrest, J. P., Franklin, F., & Brouillette, C. G. (1985). "Role of the hydrophobic face of amphipathic helices in the interaction of high-density lipoproteins with lecithin cholesterol acyltransferase." Journal of Biological Chemistry, 260, 10256-10262. 21. Kariyazono, H., Ito, M., Toma, T., Ohkubo, T., Takimoto, Y., & Saito, H. (2016)."Development of a novel amphipathic a-helical peptide for effective siRNA delivery." Journal of Peptide Science, 22, 116-122.22. Lichty, J. J., Malecki, J. L., Agnew, H. D., Michelson-Horowitz, D. J., & Tan, S. (2005)."Comparison of affinity tags for protein purification." Protein Expression and Purification, 41 , 98-105.23. Zhao, X., Wu, F., & Bhattacharya, C. (2013). "An overview of protein tags for purification and detection." Journal of Analytical Methods in Chemistry, 2013, Article ID 625389.24. Kimple, M. E., Brill, A. L., & Pasker, R. L. (2004). "Overview of affinity tags for protein purification." Current Protocols in Protein Science, Chapter 9, Unit 9.1-9.1.19.25. Giannone, R. J., et al. (2014). Protein Affinity Tags: Methods and Protocols. Methods in Molecular Biology, Vol. 1177, Humana Press.26. Scheraga, H. A. (1992). "Recent advances in theoretical studies of protein folding." Reviews in Computational Chemistry, 1, 142-173.27. Liu, J. K. H., Carmichael, D. F., & Morrison, S. L. (1997). "Design of linker peptides for fusion proteins." Proceedings of the National Academy of Sciences of the United States of America (PNAS), 94, 5525-5530.28. Kim, Y. G., Chaudhary, N., & Massey, R. J. (1996). "Efficient generation of single-chain Fv antibodies for use in gene therapy." Proceedings of the National Academy of Sciences of the United States of America (PNAS), 93, 1156-1160.29. Chaudhary, V. K., Queen, C., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., & Pastan, I. (1990). "A recombinant immunotoxin consisting of two antibody variable domains fused to pseudomonas exotoxin." Proceedings of the National Academy of Sciences of the United States of America (PNAS), 87, 1066-1070.30. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988). "Single-chain antigen-binding proteins." Science, 242, 423-426.31. Yarden, Y. & Sliwkowski, M. X. (2001). "Untangling the ErbB signalling network." Nature Reviews Molecular Cell Biology, 2(2), 127-137.32. Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., & Chen, L.(2001). "B7-H3: a costimulatory molecule forT cell activation and IFN-y production." Nature Immunology, 2(3), 269-274.33. Leitner, J., Klauser, C., Pickl, W. F., Stockl, J., Majdic, O., Bardet, A. F., Steger, M. M., & Steinberger, P. (2009). "B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREM-like transcript 2 interaction." Eur J Immunol. 2009 Jul;39(7): 1754-64.
Claims
Claims1. A lipid-peptide conjugate comprising:(a) at least one lipid binding peptide comprising at least one lipid binding domain, wherein the lipid binding domain comprises at least one hydrophobic amino acid and at least one hydrophilic amino acid, andwherein the lipid binding peptide is a secondary amphipathic peptide;(b) at least one lipid; and(c) at least one active agent.
2. A lipid-peptide conjugate according to claim 1 , wherein at least 15% of the amino acids of the amino acid sequence of the at least one lipid binding domain are proline.
3. A lipid-peptide conjugate according to claim 1 or 2, wherein the at least one lipid binding domain comprises at least one proline and at least one arginine, wherein the at least one proline and the at least one arginine are tandemly interspersed.
4. A lipid-peptide conjugate according to any one of claims 1-3, wherein the at least one lipid binding domain comprises the amino acid sequence ZXZPPP (SEQ ID NO: 10) wherein Z is any hydrophobic amino acid and X is any hydrophilic amino acid.
5. A lipid-peptide conjugate according to claim 1 , wherein the at least one lipid binding domain comprises at least one lysine and at least one leucine, wherein the at least one lysine and the at least one leucine are tandemly interspersed.
6. A lipid-peptide conjugate according to claim 1 , wherein the at least one lipid binding domain comprises 20 to 100 domains? having the amino acid sequence LKKLLK (SEQ ID NO: 11).
7. A lipid-peptide conjugate according to claim 1 , wherein the at least one lipid binding domain comprises at least 20 to 100 domains having the amino acid sequence LEK.
8. A lipid-peptide conjugate according to claim 1 , wherein the at least one lipid binding domain is an apolipoprotein selected from apolipoprotein A; Apolipoprotein B; Apolipoprotein C; Apolipoprotein D; Apolipoprotein E; Apolipoprotein F; Apolipoprotein H; Apolipoprotein J; Apolipoprotein L; and Apolipoprotein M; or a fragment each thereof.
9. A lipid-peptide conjugate according to claim 1 , wherein the at least one lipid binding domain comprises an amino acid sequence selected from SEQ ID NO: 11 to SEQ ID NO: 25.
10. A lipid-peptide conjugate according to any one of claims 1-9, wherein the lipid binding peptide further comprises at least two antigen binding domains; wherein the at least one lipid binding domain is located between the at least two antigen binding domains.
11. A lipid-peptide conjugate according to claim 10, wherein at least one antigen binding domain comprises an antibody, a fragment antigen-binding region of an antibody, a variable region of an antibody, a variable region of a heavy chain of an antibody, a variable region of a light chain of an antibody, ora variable region of a heavy chain of an antibody and a variable region of a light chain of an antibody.
12. A lipid-peptide conjugate according to claim 10 or 11 , wherein a first antigen binding domain comprises a variable region of a heavy chain of an antibody, and a second antigen binding domain comprises a variable region of a light chain of an antibody, wherein the variable region of the heavy chain and the variable region of the light chain together form a fragment antigen-binding region of an antibody.
13. A lipid-peptide conjugate according to claim 10 or 11 , wherein a first antigen binding domain comprises a variable region of a heavy chain of an antibody and a variable region of a light chain of an antibody; and a second antigen binding domain comprises a variable region of a heavy chain of an antibody and a variable region of a light chain of an antibody, wherein the variable region of the heavy chain and the variable region of the light chain together form a fragment antigen-binding region of an antibody.
14. A lipid-peptide conjugate according to any one of claims 10-13, wherein the at least one antigen binding domain comprises at least one linker, wherein the at least one linker has an amino acid sequence selected from SEQ ID NO:1 to SEQ ID NO:9 or SEQ ID NO:26 to SEQ ID NO:29.
15. A lipid-peptide conjugate according to any one of claims 10-14, wherein the at least one antigen binding domain comprises at least one cap peptide, wherein the at least one cap peptide has an amino acid sequence selected from SEQ ID NO: 30 to SEQ ID NO: 35.
16. A lipid-peptide conjugate according to any one of claims 1-15, wherein the lipid binding peptide further comprises at least one intermolecular linker, wherein the at least one intermolecular linker comprises an amino acid sequence selected from SEQ ID NO: 56 to SEQ ID NO: 68.
17. A lipid-peptide conjugate according to any one of claims 1-16, wherein the lipid binding peptide comprises an amino acid sequence selected from SEQ ID NO: 36 to SEQ ID NO: 54 and SEQ ID NO: 80 to SEQ ID NO: 85.
18. A lipid-peptide conjugate according to any one of claims 1-17, wherein the at least one lipid is selected from a phospholipid selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), cardiolipin; a sphingolipid selected from sphingomyelin and a glycolipid, and combinations thereof; a cationic lipid selected from 1 ,2-di-Q-octadecenyl-3-trimethylammonium-propane (DOTMA), 1 ,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE) and 1 ,2-dioleoyl-3- trimethylammonium-propane (DOTAP), and ionizable lipids selected from 4 Hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate (ALC-0315), 8-[(2- hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1 -octylnonyl ester (SM-102), Q-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino) (DLin-MC3-DMA (MC3)), and 1 ,2-dioleoyl-3-dimethylammonium propane (DODAP).
19. A lipid-peptide conjugate according to any one of claims 1-18, wherein the at least one active agent is selected from a molecule, nucleic acid, an oligonucleotide, a ribonucleic acid, a deoxyribonucleic acid, an amino acid, and a protein.
20. A lipid-peptide conjugate according to any one of claims 1-18 for use in therapy.
21. A method of preventing or treating a disease or disorder in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically-effective amount of a lipid-peptide conjugate according to any one of claims 1-18.
22. Use of a lipid-peptide conjugate according to any one of claims 1-18 in the manufacture of a medicament for preventing or treating a disease or disorder.
